neurology & neurosurgery - nyulangone.org · philip k. moskowitz, md professor and chair of...

NYU LANGONE HEALTH

550 First Avenue, New York, NY 10016

NYULANGONE.ORG

Neurology & Neurosurgery2017 YEAR IN REVIEW

AdvancedTECHNOLOGY FOR NEUROSURGICAL IMAGING

214NEUROLOGY FACULTY

# 10IN U.S. NEWS & WORLD REPORT

1 MESSAGE FROM THE CHAIRS

2 FACTS & FIGURES

4 2017 IN BRIEF

10 2017 IN DEPTH

11 Epilepsy Advances Target Seizure Activity, Severity

13 Complex Case: Resection of a Deep Thalamic Cavernous Malformation

16 Gamma Knife Radiosurgery—Versatility in Tumor and AVM Treatment

18 Novel Optical Assessments Offer Insight into Neurological Conditions

20 Complex Case: Intramedullary Cavernoma Calls for Intervention

22 Promising Research Fuels the Pursuit of New Alzheimer’s Pathways

24 Novel Neuromodulation Approaches for Movement Disorders

26 ACADEMIC ACTIVITIES

34 FACULTY

35 LEADERSHIP

Contents

On the cover: Nerve fibers

Produced by: Office of Communications and Marketing, NYU Langone Health Writer: Royce Flippin Design: Ideas On Purpose, www.ideasonpurpose.com Primary Photographer: Karsten Moran Printing: Allied Printing Services, Inc.

Philip K. Moskowitz, MD Professor and Chair of Neurology

Professor of Neurology and Ophthalmology

Whether refining surgical techniques, uncovering novel neurodegenerative disorder treatments, or investigating brain cancer’s biological underpinnings, our faculty have extended our leadership in every aspect of neurological medicine.

Fueling this leadership are cutting-edge diagnostic imaging techniques and applications, identified through interdisciplinary collaboration. Our Gamma Knife radiosurgery program has enabled noninvasive treatment of multiple brain tumors, and our Center for Neuromodulation is refining the latest generation of deep brain stimulation (DBS) devices for Parkinson’s disease. DBS is also under investigation for Tourette’s syndrome, as we explore the benefits of both DBS and Gamma Knife radiosurgery for obsessive-compulsive disorder. The complex cases highlighted in this report are a testament to how our neurosurgeons use these advances to achieve previously impossible feats.

Our faculty continue to pioneer and advance novel technology for both diagnosis and treatment. Our neuro-ophthalmologists are using optical coherence tomography to expand the diagnostic criteria for multiple

sclerosis, and the Division of Neuro-Ophthalmology is analyzing eye movements to aid in the diagnosis of a variety of neurological disorders. At the Multiple Sclerosis Comprehensive Care Center, clinicians are demonstrating the efficacy of low-voltage transcranial direct current stimulation for MS-related fatigue. Collaboration between the Brain Tumor Center and NYU Langone pathologists has enabled the first U.S.-certified use of 450K methylation technology in tissue evaluations.

Interdisciplinary collaboration is central to advancing our clinical and research progress. Our close partnerships with Neuroradiology and other specialties have enabled such advances as MRI perfusion techniques to monitor brain tumor treatment response. At the Eye Movement Testing Lab, teamwork with our Concussion Center colleagues has evolved concussion diagnosis, and our stroke program—part of the integrated Center for Stroke and Neurovascular Diseases—benefits from close work with specialists across NYU Langone. Our cross-disciplinary expertise helps us unravel the most complex clinical puzzles, as demonstrated by recent

insights revealed by our faculty in the Division of Headache Medicine.

Promising treatments emerging from clinical trials in the Center for Cognitive Neurology and our epilepsy, MS, and Parkinson’s programs are quickly put into practice for the benefit of our patients. Aided by one of the most extensive and complex tissue banks in the country, we are advancing the understanding of disease pathology and treatment response that expands our clinical options. Prominent new physician recruits at the growing Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders bring enhanced research and clinical rigor to our programs.

With our dedicated clinicians’ and researchers’ unique blend of focused collaboration and innovation, we are ready to produce unprecedented change in our field. Together, we will continue to make promising discoveries that transform outcomes—and realize the great promise that neurological and neurosurgical advances hold for our patients.

Dear Colleagues and Friends:

MESSAGE FROM THE CHAIRS

Chair, Department of Neurosurgery

Associate Professor of Neurosurgery and Otolaryngology

JOHN G. GOLFINOS, MDSTEVEN L. GALETTA, MD

For the departments of Neurology and Neurosurgery at NYU Langone Health, 2017 was a year of continued advancement. Our record of excellence is reflected in our top 10 ranking among the nation’s most elite programs, a testament to our cross-specialty impact.

1Neurology & Neurosurgery 2017 | NYU Langone Health

Neurology and Neurosurgery

FACTS & FIGURES

PATIENT CARERESEARCH FACULTY

70 + ONGOING CLINICAL TRIALS IN NEUROLOGY and

30 +ONGOING CLINICAL TRIALS IN NEUROSURGERY

20 +YEARS OF CONTINUOUS NIH FUNDINGfor a single R01 grant in neurosurgery

30 + ONGOING RESEARCH STUDIESon the treatment and prevention of neurocognitive disorders

$11.75 M NEUROLOGY GRANT FUNDING awarded in 2017

18RESIDENT PRESENTATIONSat the American Academy of Neurology 2017 annual meeting

5,100 +NEUROSURGICAL CASES

560 +GAMMA KNIFE CASES

1,200+SPINAL NEUROSURGERY CASES

77,000 +NEUROLOGY OUTPATIENT VISITS

35NEUROLOGY FACULTY AND RESIDENTSinvolved in ongoing quality and safety projects

27 FULL-TIME NEUROSURGERY FACULTY with more than 30 part-time and affiliated faculty

214 NEUROLOGY FACULTY20 joined in 2017

91 RESIDENCY POSITIONS75 in neurology 16 in neurosurgery

ACCOLADES

#10IN THE COUNTRY for neurology and neurosurgery in U.S. News & World Report’s “Best Hospitals”

#1 in the NationFOR LOWEST MORTALITY SCORE IN CRANIAL NEUROSURGERYas awarded by Vizient, Inc.

2 NYU Langone Health | Neurology & Neurosurgery 2017

NYU Langone Health

5 Star RatingFROM CMS HOSPITAL COMPARENYU Langone Health is the only full-service hospital in New York State and one of 9 percent of hospitals nationwide to receive a five-star rating from the Centers for Medicare and Medicaid Services (CMS). The rating reflects overall safety, quality, and patient experience.

#12IN THE NATION BEST MEDICAL SCHOOLS FOR RESEARCHand a leader in innovation in medical education, including accelerated pathways to the MD degree

LeaderIN QUALITY CARE AND PATIENT SAFETYFor the past four years, NYU Langone has received top rankings for overall patient safety and quality of care from Vizient, Inc., formerly the University HealthSystem Consortium. In 2017, NYU Langone received two significant awards from Vizient—the Bernard A. Birnbaum, MD, Quality Leadership Award and the Ambulatory Care Quality and Accountability Award for demonstrated excellence in delivering high-quality, patient-centered outpatient care.

#19IN THE NATIONand nationally ranked in 12 specialties: Rehabilitation, Orthopedics, Rheumatology, Neurology & Neurosurgery, Geriatrics, Urology, Cardiology & Heart Surgery, Gastroenterology & GI Surgery, Diabetes & Endocrinology, Pulmonology, Cancer, and Nephrology

View of NYU Langone Health’s main Manhattan campus, including renderings of the new Science Building (left) and the Helen L. and Martin S. Kimmel Pavilion (right), both set to open in 2018. (Image credit: Ennead Architects)


Research and Innovation Transform Clinical Outcomes

Homing In on Cutting-Edge Headache Therapies

In the newly expanded Division of Headache Medicine, specialists are leading clinical trials aimed at delivering new treatment options for chronic or intractable headaches.

In one phase III clinical trial, investigators are testing an experimental drug that works by blocking calcitonin gene–related peptide (CGRP), a neurotransmitter thought to trigger migraines. Researchers are exploring whether eptinezumab, administered via injection once every 12 weeks, can prevent chronic and frequent episodic migraines. “The trials have been very promising, with minimal side effects,” says Lawrence C. Newman, MD, professor of neurology and director of the Division of Headache Medicine. “Results tend to be seen within a week or so—much faster than with other medications.”

BREAKING THE HEADACHE CYCLE

The new drug would add to the range of headache treatments currently available, including those offered at a new infusion center at NYU Langone, where patients are administered targeted treatments that often provide relief within the hour.

The division is also teaming with physicians at NYU Langone’s Concussion Center and vestibular rehabilitation program to increase our understanding of the mechanisms of headache associated with head trauma. “Each member of our collaborative team is interested in sharing their expertise to enhance the field,” notes Dr. Newman. Recently, headache faculty began offering an elective rotation in headache medicine, in which neurology residents are exposed to the full range of headache disorders.

“Although just a few drugs are currently FDA-approved for migraine prevention, our growing understanding of headache mechanisms continues to augment our armamen-tarium of treatments that provide relief,” adds Dr. Newman.

Adelene E. Jann, MD, and Lawrence C. Newman, MD

2017 IN BRIEF

Read more onPAGE 11

Advances in Epilepsy Target Seizure Activity and Severity

At the Comprehensive Epilepsy Center, recent research and clinical trials are shedding new light on ways to reduce the severity of seizures and provide better quality of life for patients with epilepsy and related disorders. Building on the center’s pioneering application of the cannabis-derived drug cannabidiol, investigators uncovered new signs of efficacy that could lead to FDA approval of the drug for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. On another drug front, a phase II trial of inhaled alprazolam is offering encouraging data demonstrating rapid absorption stems oncoming seizures, supporting use of the drug as a rescue medication. Researchers are also continuing their efforts to unravel the mystery of sudden unexpected death in epilepsy (SUDEP). Spurred by newly uncovered estimates of SUDEP prevalence indicating that earlier estimates were understated, the center is pursuing a new technology that would use heightened nervous system activity to warn family members of SUDEP onset—and potentially save lives.


Research Targets Triggers and Symptoms of Multiple Sclerosis

NYU Langone’s Multiple Sclerosis Comprehensive Care Center continues to uncover and pioneer novel approaches to multiple sclerosis (MS) symptom control, disease management, and treatment.

In a seminal 2018 publication in the Journal of Neurology, Neurosurgery & Psychiatry, center researchers identified an important potential environmental trigger for MS, showing that young MS patients with a lower intake of saturated fat had fewer relapses compared to those with a high intake. The new findings are part of an ongoing investigation of environmental factors that can exacerbate genetic predisposition to pediatric MS, with other potential risk factors including childhood obesity, pesticide exposure,

secondhand smoke, and childhood trauma. “We’re making significant headway in identifying these environmental triggers,” notes center director Lauren B. Krupp, MD, the Nancy Glickenhaus Pier Professor of Pediatric Neuropsychiatry. “It’s my belief that what we’re finding in pediatric MS is also relevant to adults with MS and likely relevant to other autoimmune diseases as well.”

Separately, a randomized controlled study published in September 2017 in the Multiple Sclerosis Journal showed that 20 sessions of portable transcranial direct current stimulation (tDCS), using an NYU Langone–customized device that delivers low-voltage electric current to the scalp, significantly alleviated MS-related fatigue in adults. “This is a major advance, since we have no effective medication to treat the fatigue MS patients so commonly experience,” notes Leigh E. Charvet, PhD, associate professor of neurology, who led the research—the first-ever controlled study of tDCS benefits for MS patients. In a complementary controlled study, published in PLOS One in 2017, an in-home, computer-based cognitive remediation program was found to significantly improve subjects’ performance on various neuropsychological tests.

Researchers also continue to analyze and publish data collected through the center’s participation in the MS PATHS project—a multicenter effort in which iPads are used to collect detailed data from patients at each clinical visit. “So far, 5,000 people have been evaluated,” notes Dr. Krupp. “We’ll combine this information with MRI data on new lesions and, eventually, outcome measurements to significantly advance clinical MS research.”

Leigh E. Charvet, PhD, and Lauren B. Krupp, MD

Complex Case: Multidisciplinary Expertise and Precision Imaging Enable Resection of a Deep Thalamic Cavernous Malformation

Vascular lesions of the thalamus are rare, and information on their surgical removal is limited to a small series of case reports. Although excellent outcomes have been reported with a well-planned surgical approach, complications of surgery include devastating neurological injury. If the lesion is left untreated, however, mass effect, secondary compromise of the microcirculation, and irritation of the cortical and subcortical tissue by local deposition of hemosiderin from microhemorrhages can result in progressive neurological deficits and seizures.

A patient with a deep thalamic cavernous malformation turned to NYU Langone after being told by multiple surgeons that his lesion was inoperable. Leveraging cutting-edge research, advanced neuroimaging techniques, and cerebrovascular surgical expertise, the multi disciplinary neurovascular team at the Center for Stroke and Neurovascular Diseases planned and executed a successful resection of this patient’s thalamic cavernoma and enabled his swift recovery.

Read more onPAGE 13


Commitment to Discovery Yields New Hope for Brain Cancer

At the Brain Tumor Center, recent research breakthroughs enabled by the center’s unique cross-disciplinary collaboration have brought investigators closer to major therapeutic and diagnostic discoveries.

In one such advance, a research team led by Dimitris G. Placantonakis, MD, PhD, assistant professor of neurosurgery, identified GPR133, a protein not normally found in the brain, on the cell surfaces of glioblastoma tissue—making it a promising target for novel therapies. “It turns out that the protein is found in all glioblastomas, and we’ve shown that when we knock it down, the tumor cells die,” says Dr. Placantonakis. The lab’s discovery, published in Oncogenesis in 2016 and Clinical Neurosurgery in September 2017, has led to a patent application and collaboration with a U.K. pharmaceutical firm and NYU Langone’s Office for Therapeutic Alliances to develop GPR133-inhibiting molecules.

In another breakthrough, published in the October 2017 issue of Cell Reports, researchers studied human neural stem cells engineered to express the IDH gene mutation that is found in the majority of low-grade gliomas. This mutation caused the neural progenitors to develop into low-grade astrocytoma-like cells. The lab discovered that the cells quickly stopped differentiating—an important first step in tumor creation—

because transcription factor SOX2 was silenced. This effect was traced back to reduced binding of chromatin organizer CTCF to DNA, which led to the unraveling of the chromatin structure and the silencing of SOX2 by preventing SOX2’s promoter from interacting with nearby enhancer elements. “We’ve uncovered one of the first examples of chromatin restructuring acting as a mechanism in tumor formation—which ultimately could apply to many cancer types,” notes Dr. Placantonakis. “In addition, our low-grade glioma model can be used to screen drugs and test new therapies.”

COLLABORATION LEADS TO DIAGNOSTIC PROGRESS

The Brain Tumor Center, working closely with molecular pathologists and neuropathologists, will become the first U.S. program certified to use genomic DNA methylation technology in clinical evaluations of brain tumors. The technology, developed for research use at NYU Langone by Matija Snuderl, MD, assistant professor of pathology and director of Molecular Pathology, can determine a brain tumor’s genetic subtype by means of a single high-throughput, comprehensive DNA test on a small brain tissue sample. “Our early adoption of this forward-thinking diagnostic

Dimitris G. Placantonakis, MD, PhD


technology puts us in a strong position to move it from the lab to the clinical setting,” says Andrew S. Chi, MD, PhD, assistant professor of medicine, neurology, and neurosurgery, chief of neuro-oncology, and co-director of the Brain Tumor Center at Perlmutter Cancer Center.

Separately, Rajan Jain, MD, associate professor of radiology and neurosurgery, has discovered a novel structural biomarker known as a T2-FLAIR mismatch, which is 100 percent indicative of a molecular subtype of glioma that carries an IDH gene mutation and lacks codeletion of chromosomes 1p and 19q. This biomarker, reported in July 2017 in Clinical Cancer Research, can be easily detected using conventional clinical brain MRI scans, without specialized equipment or invasive protocols. “It’s what we’re all looking for—a way to diagnose a tumor’s molecular subtype without having to open the skull,” says Dr. Chi. In another project, Dr. Jain is pioneering the clinical use of MRI perfusion to better visualize how certain tumors respond to therapy.

“It’s becoming clear that molecular subtyping is necessary for optimal management of brain tumors,” notes Dr. Chi, “since each subtype may respond differently to specific therapies.” Breakthroughs, then, will come not only from developing new classes of drugs and immune therapies, but also from identifying which molecular subtype is sensitive to a given therapy. “That’s why developing rapid, robust molecular subtyping diagnostics that can easily be applied to the clinical setting is so critical,” adds Dr. Chi.

Axial T2 and FLAIR MRIs showing the T2-FLAIR mismatch imaging sign for the preoperative diagnosis of IDH mutated and 1p/19q non-codeleted gliomas

Novel Optical Assessments Provide New Windows into Neurological Conditions

As researchers and clinicians pursue new modes of treatment for complex neurological diseases, advancements in optical coherence tomography (OCT)—capable of delivering images at 1,000 times the resolution of MRI—and the expansion of OCT applications have enhanced clinicians’ capacity to diagnose and treat these conditions. OCT and other vision-based diagnostic tools have enabled the visualization of optic nerve lesions associated with multiple sclerosis, adding weight to efforts to incorporate these markers in diagnostic criteria for the disease. In traumatic brain injury, the new visualization techniques are being used to elucidate the mechanisms behind retinal loss associated with concussion and other neurological conditions.

Read more onPAGE 18

Gamma Knife Radiosurgery Offers Versatility in Treating Brain Tumors and AVMs

Ongoing research continues to uncover and enhance the efficacy of Gamma Knife radiosurgery for an expanding array of conditions, including cancer and arteriovenous malformations (AVMs). Aided by enhanced surveillance, physicians at NYU Langone are tracking and targeting tumors more precisely and employing Gamma Knife’s versatility to treat conditions previously considered untreatable, improving options and outcomes for the most complex cases. The approach is illustrated by two recent, very different cases in which Gamma Knife radiosurgery’s precision proved invaluable: the successful treatment of a patient with more than 25 individual tumors and the highly delicate resolution of an otherwise unresectable AVM.

Read more onPAGE 16


Collaboration among Neuroradiologists and Neurosurgeons Enables Neuroimaging Firsts

The partnership between NYU Langone neurosurgeons and neuroradiologists contributes to continued advancements in the field of neurosurgical planning, pushing the limits of imaging technology and fundamentally shifting approaches to surgery. Among recent innovations: reduced field-of-view diffusion MRI; three-dimensional volumetric MRI; and advanced diffusion tractography, applied to spinal neurosurgery for the first time at NYU Langone. These technologies provide real-time maps of spinal cord tumor location and the relative positions of important spinal cord white matter tracts to improve safety and surgical outcomes.

“Imaging science experts have developed newer techniques for the conventional diffusion tractography already used by our neuroradiologists, giving us unprecedented visualization of brain and spinal cord structures,” explains Timothy M. Shepherd, MD, PhD, assistant professor of radiology. Dr. Shepherd’s team is working on a novel protocol that will enable surgeons to visualize important eloquent white matter pathways, such as the arcuate fasciculus, even in the presence of edema. “Edema or mass effect from tumors can impair our ability to visualize these pathways with conventional tractography for operative planning and is a major imaging challenge in neurosurgery,” says Dr. Shepherd. “By seeing through edema effectively, we can enhance the accuracy of the brain maps we provide for neurosurgical navigation—and thus reduce patient risk.”

PROGRESS IN IMAGING ENABLES PRECISION

Neuroradiologists are also preparing to publish their novel use of simultaneous multi-slice diffusion and track density imaging to directly visualize key anatomical targets in the brain for functional neurosurgery applications. “The sequence has been around for a few years, but it’s never been altered in this way to make it practical for use in patients. Our collaboration with colleagues in imaging physics, neurology, and neurosurgery helped us realize its value for functional neurosurgery,” explains Dr. Shepherd. With this sequence, the modified images show the structures and inter connections in the thalamus, subthalamus, and basal ganglia regions in more detail than was previously possible, an advance that will help surgeons to more clearly visualize where deep brain stimulation electrodes are being placed.

“This is another example of how enhanced imaging is moving us away from indirect targeting based on anatomical atlases,” adds Dr. Shepherd. “The methods our work uncovers could have a profound impact on functional neurosurgery—ultimately improving outcomes and decreasing risk.”

Complex Case: Cutting-Edge Neuroimaging Adapted to Safely Resect a Challenging Spinal Tumor

The use of newer imaging technologies such as advanced diffusion tensor imaging (DTI) has enabled safe resection of once-inoperable spinal cord tumors. Initially pioneered for brain surgery, the technology was used in the spine for the first time by Anthony K. Frempong-Boadu, MD, associate professor of neurosurgery and director of the Division of Spinal Surgery. This was two years before a 29-year-old patient presented with a risky intra-medullary cavernoma whose removal carried the risk of permanent morbidity. These rare tumors—only a small fraction of all the central nervous system lesions that are seen—are so complex that few centers are equipped to treat them. For this patient, Dr. Frempong-Boadu teamed with neuroradiologists to apply the leading-edge DTI approach, creating visual touchpoints for the surgery that enabled resection of the tumor while leaving the patient’s neurological function—and quality of life—intact.

Read more onPAGE 20

New MRI sequences for improved preoperative planning and real-time intraoperative surgical navigation in cervical spinal cord tumors: a gradient-based sequence for gray-white differentiation (A), a cardiac-gated high-angular resolution diffusion protocol to precisely locate the corticospinal tracts and dorsal columns without tractography (B), and greatly improved tractography (C)


Novel Drugs and Biological Discoveries Accelerate Hunt for an Alzheimer’s Cure

With 12 ongoing clinical trials, NYU Langone’s Center for Cognitive Neurology is one of the world’s most active centers for research on Alzheimer’s disease and other neurocognitive disorders. The center’s more than 70 researchers are working across a range of disciplines to unravel the root causes of these conditions. Research into immunotherapies for Alzheimer’s and related dementias is one of the pathways offering promise—and the recently published groundbreaking studies are paving the way for human trials. At the same time, investigations into the biological mechanisms behind these conditions—including several studies funded by the National Institutes of Health—are yielding new insights into the proteomic and genetic markers of Alzheimer’s that could eventually lead to a preventive treatment.

Read more onPAGE 22

Innovative Neuromodulation Approaches for Movement Disorders

At the Center for Neuromodulation, new and expanded applications of deep brain stimulation (DBS) and related innovations are targeting symptoms and enhancing quality of life for patients with Parkinson’s disease, tremor, and other disorders.

The center has been involved in clinical trials of newer DBS technologies and devices, giving clinicians a unique view of their efficacy in delivering electrical stimulation to targeted brain regions to reduce motor symptoms of Parkinson’s, essential tremor, and dystonia. The DBS technologies provide additional options—and new therapeutic targets—for personalizing treatment of Parkinson’s symptoms while limiting side effects and also offer new hope as an off-label treatment for the debilitating symptoms of severe Tourette’s syndrome. The expanding field of neuromodulation also includes MRI-guided focused ultrasound, which targets areas of the brain linked to tremor and other symptoms, eliminating the need for surgery while potentially mitigating symptoms.

Read more onPAGE 24

New Leadership Renews Commitment to Translational Research in Movement Disorder Treatment

With newly appointed leadership, the Division of Parkinson’s and Movement Disorders at NYU Langone is increasing its focus on translational research. Steven J. Frucht, MD, professor and associate chair of neurology and director of NYU Langone’s Division of Parkinson’s and Movement Disorders, and Andrew S. Feigin, MD, professor and associate chair of neurology and executive director of the Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, bring a mix of experience that will help the division cultivate new pathways for transforming its research discoveries into new therapies.

Both Dr. Frucht and Dr. Feigin have launched clinical trials testing novel vaccines and antibody drugs designed to block toxic brain proteins, including alpha-synuclein and tau proteins, thought to contribute to movement disorders. In addition, institute researchers will investigate novel methods of administering symptom-relieving medications such as subcutaneous infusion of levodopa and dopamine agonists, and new imaging techniques that may yield movement disorder biomarkers.

Clinicians and researchers will also work closely with colleagues across NYU Langone to develop a new biological understanding of movement disorders and refine leading-edge diagnostic and treatment approaches—including deep brain stimulation for Parkinson’s symptoms and eye movement tracking technology for diagnosis—to improve quality of life for patients with these disorders.

“We have a unique opportunity to establish the institute as a leading center for clinical and translational research for movement disorders,” says Dr. Frucht, who has been involved in many Parkinson’s studies as well as pilot studies of refractory movement disorders. “Together, we will provide multidisciplinary care while simultaneously advancing clinical research,” adds Dr. Feigin.

Steven J. Frucht, MD, and Andrew S. Feigin, MD


Pushing Treatment Boundaries through Collaboration and Discovery

2017 IN DEPTH

John G. Golfinos, MD, and Andrew S. Chi, MD, PhD


EPILEPSY

Epilepsy Studies Uncover New Options for Shortening Seizures—and Extending Lives

A growing body of knowledge, informed by recent investigations and clinical trials at the Comprehensive Epilepsy Center, could equip physicians and family members with new tools for stemming seizures and preventing sudden death in patients with epilepsy and related disorders.

SUCCESSFUL CANNABIDIOL TRIAL HERALDS FIRST TREATMENT FOR DRAVET-RELATED SEIZURES

Epileptologists have uncovered a potential new treatment option in the cannabis-derived drug cannabidiol (Epidiolex), shown to significantly reduce convulsive seizures related to Dravet syndrome, a rare pediatric-onset disorder for which there are currently no U.S.-approved medications.

The Dravet trial, published in May 2017 in The New England Journal of Medicine,

found that cannabidiol in liquid form reduced seizures in children and young adults with Dravet syndrome by 39 percent on average. Two other soon-to-be-published studies found that the drug also reduced the frequency of drop seizures in individuals with Lennox-Gastaut syndrome, another form of epilepsy that often resists drug treatment.

On the basis of these studies, cannabidiol will soon be formally submitted for FDA approval as a treatment for both Dravet and Lennox-Gastaut

syndromes, according to lead author Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center. “The FDA could approve it as soon as mid-2018, which would be a huge milestone,” says Dr. Devinsky. NYU Langone Health has been involved in cannabidiol’s pharmaceutical development from the very beginning, having hosted the first meeting with the drug’s manufacturer to discuss these trials five years ago.

Orrin Devinsky, MD


EPILEPSY

INHALED ALPRAZOLAM SHOWS PROMISE AS A PRE-SEIZURE RESCUE MEDICATION

Separately, NYU Langone researchers are spearheading a phase II clinical trial testing an inhaled form of the benzodiazepine alprazolam (Xanax) as a rescue medication for incipient seizures. “Oral benzodiazepines are already used to shorten the duration of seizure clusters, but they don’t work fast enough to actually abort a seizure when a person feels it coming on,” explains Jacqueline A. French, MD, professor of neurology and director of Translational Research and Clinical Trials at the Comprehensive Epilepsy Center. “This approach uses a device that vaporizes the medication so the lungs absorb it at a rapid rate, nearly equivalent to an intravenous dose.”

A preliminary study with individuals susceptible to light-induced seizures showed that inhaled alprazolam produced an anti-seizure effect within two minutes. Through a connection made via the

NYU Langone–affiliated nonprofit FACES (Finding a Cure for Epilepsy and Seizures), researchers are now collaborating with a start-up enterprise to support the yearlong efficacy trial.

UNRAVELING THE MYSTERY OF EPILEPSY-RELATED SUDDEN DEATH

Ongoing research continues to unravel the prevalence and biology of SUDEP. One finding, published in August 2017 in Neurology, suggests that the annual number of deaths from SUDEP in the United States could actually be far higher than the reported and widely accepted number of 3,000. The recalculation was based on an examination of data for all sudden cardiac deaths in the San Francisco area over a three-year period. Researchers reviewed autopsy and medical records of any decedents with a history of seizures or epilepsy, and concluded that the number of definite or possible SUDEP cases was three times

greater than the number reported by the medical examiner.

“Combine this new estimate with the number of deaths of people with epileptic seizures that result in drowning, car accidents, or falls,” says Dr. Devinsky, “and it becomes clear that epilepsy-related death is an underestimated and under-addressed public health problem.”

To address this issue, researchers are studying a wrist sensor that monitors sympathetic nervous system activity via the skin. The goal is twofold: to examine the link between heightened electro-dermal activity and the onset of seizures and to explore the device’s usefulness in warning family members of a potential SUDEP-causing seizure.

“Our continued research has revealed one more clue we can pursue to unravel the mystery of SUDEP,” notes Dr. Devinsky. “In time, with further resources devoted to understanding how these deaths occur, we hope to prevent them.”

HUMAN EPILEPSY PROJECT: HUNTING FOR BIOMARKERS TO OVERCOME TREATMENT RESISTANCE

In an effort to find biomarkers enabling early identification of

treatment-resistant epilepsy, the Human Epilepsy Project

recently enrolled 500 newly diagnosed focal-seizure epilepsy

patients in a multisite study co-led by NYU Langone. For three

years, researchers will follow patients in the United States,

Europe, and Australia, gathering biological information including

DNA and blood samples, urinalyses, EEG readings, and a special

MRI evaluation while also tracking participants’ response to

epilepsy medications.

This information is being logged in a data bank, where it can be

mined by collaborating scientists. “We know that a third of

people with epilepsy won’t respond well to any medication, but

currently there’s no way to determine at the onset of treatment

who they are,” says Dr. French. “This is an effort to understand

the biological drivers behind that resistance.”

Three proposals from scientific groups seeking to examine

specific biomarkers have been green-lit, she adds. Two will

explore autoimmune factors, believed to trigger epilepsy in some

cases. A third group is looking at a blood biomarker involved in

inflammation, which is hypothesized to exacerbate seizures.

The project has already yielded one unexpected discovery:

Many study subjects were found to have experienced subtle

seizures for months or years before their epilepsy diagnosis.

“People can experience numerous safety issues if their

diagnosis is delayed,” notes Dr. French. “This finding indicates

that we need to better help the public and the medical

community to identify seizures.”

Jacqueline A. French, MD


NEUROVASCULAR

Complex Case: Progressive Symptoms Point to the Resection of a Deep Thalamic Cavernous Malformation

Previously advised against surgery because of the risky location of his thalamic lesion, a patient found new hope in NYU Langone Health’s Center for Stroke and Neurovascular Diseases and an advanced approach carefully coordinated by a multidisciplinary team.

In the 16 years since a right thalamic

cavernous malformation was identified on

MRI imaging, the patient had had multiple

hemorrhages, a relatively common

complication of thalamic cavernous

malformations. In addition to expansion of

the lesion, the patient had also experienced

progressive hemisensory loss and

dysesthetic pain syndrome, making

treatment imperative. “The patient had

been told by other surgical teams that the

cavernous malformation was inoperable,

because there was increasing concern

about progressive functional damage,”

says Howard A. Riina, MD, professor of

neurosurgery, neurology, and radiology.

“It was critical to find a surgical approach

that could help mitigate potential risks,

including left hemiplegia and venous

infarction of the thalamus.”

PREOPERATIVE PLANNING AND TARGETED MAPPING SET TRAJECTORY FOR SUCCESS

The optimal resection approach for a

thalamic cavernous malformation depends

on the location of the malformation in the

thalamus. This patient’s malformation

was in the lateral posteroinferior region,

bordered anteriorly by the medial and

lateral thalamus, so that a parieto-occipital

transventricular approach through the

superior parietal lobe could be used to

bypass the optic radiations and the

somatosensory region.

“We decided that the best way to access the

malformation safely was to perform the

procedure through a small tube, a minimally

invasive approach typically used for brain

tumors,” explains Dr. Riina, who handled the Howard A. Riina, MD


cerebrovascular aspects of the surgery.

“Rather than cut into the thalamus, we

found a very simple trajectory through the

ventricle, from which I could extend into the

thalamus to gain access to the lesion.”

Advanced imaging was imperative to guide

the surgeons’ precision approach. Using

Surgical Theater’s surgical planning

software to combine MRI, MR angiography,

and diffusion tensor imaging, the team

selected a target point. The combination of

the data sets into a three-dimensional

surgical planning model allowed the

surgeons to map multiple trajectories and

choose the best one: through the posterior

medial parietal lobe, superior to the optic

radiations and posterior to the

somatosensory cortex, to the lesion. The

borders of the cavernous malformation

were simultaneously drawn in the Brainlab

image guidance system to create a lesion

volume around the target. This combined

approach, using surgical planning software

and image guidance, provided surgical

access that transversed the least amount of

brain tissue, significantly reducing the risk

of complications and permanent injury.

INTRAOPERATIVE PROJECTIONS IMPROVE SURGICAL PRECISION

With planning in place, Dr. Riina was joined

in the operating room by John G. Golfinos,

MD, associate professor of neurosurgery

and otolaryngology and chair of the

Department of Neurosurgery, and

Jeffrey H. Wisoff, MD, professor of

neurosurgery and pediatrics. Continuous

stereotactic guidance and tractography

supported the procedure’s navigation,

while Surgical Theater and Brainlab

projections oriented the surgeons to the

limits of the tumor, confirmed the approach

vector, and guided the placement of the

tubular retractor. The surgeons worked as

a team throughout the procedure, with

each surgeon rotating in at critical

junctures to lend his specific expertise.

After performing a circular craniotomy,

the dura was opened in cruciate fashion.

The operating microscope was introduced

through a prominent sulcus selected as

the entry point. To displace delicate

tissues and folds of the brain—and limit

intraoperative damage—a tubular retractor

was advanced along the chosen trajectory

into the atrium of the lateral ventricle,

entering the thalamus at a point identified

by the microscope and pointer as superior

and lateral to the choroid plexus. Precise

navigation for microdissection was enabled

by visual tracking.

Immediately after making a small

corticectomy, the surgeons encountered

hemosiderin staining within the tissue.

A large developmental venous anomaly was

identified medially and preserved intact.

“The lesion was only a few millimeters deep

to the surface, just as we had seen in

presurgical imaging,” Dr. Riina recalls. “We

worked in turns to resect the cavernous

malformation and evacuate old hemorrhage

products so that we could ensure that we

reached the borders in all planes.”

The thorough excision of the malformation

was enabled by comprehensive, imaging-

aided preplanning that allowed the surgical

team to choreograph the removal without

leaving a trace—and set the patient on a

swift path to recovery. “Two days after the

operation, the patient went home,” reports

Dr. Golfinos. “This is a remarkable outcome

given the lesion’s treacherous location and

the precision approach it demanded.”

MULTIDISCIPLINARY COLLABORATION AND CONCENTRATED RESOURCES ENHANCE NEUROVASCULAR CARE

This achievement, notes Dr. Riina, is a credit

to the collaboration and teamwork fostered

by experts in the Center for Stroke and

Neurovascular Diseases. “These lesions

would be extraordinarily difficult for

surgeons to treat without the concentration

of advanced neuroimaging, protocols, and

neurosurgical expertise available at

NYU Langone,” he adds. “Our center is

unique in that respect, giving patients with

unique and complex cases options for

successful surgical treatment that are

simply unavailable elsewhere.”

NEUROVASCULAR

Three-dimensional preoperative imaging was used to assess the location of the pathology and relevant anatomy.

The final trajectory—through the superior parietal lobe—was identified as the best approach for a successful resection.


NEW CENTER PROVIDES AN INTEGRATED FRAMEWORK FOR STROKE AND OTHER NEUROVASCULAR CARE

Launched in 2017, the NYU Langone Center for Stroke and

Neurovascular Diseases has established a multidisciplinary

clinical and research hub for its preeminent stroke and

neurovascular capabilities.

“We seized the opportunity to create a highly specialized

center that integrates the latest research, educational, and

clinical advances for patients with stroke and neurovascular

disease,” says the center’s director, Howard A. Riina, MD,

professor of neurosurgery, neurology, and radiology.

The center comprises the institution’s renowned

Comprehensive Stroke Center and its cerebrovascular

neurosurgery program, as well as its neurocritical care, stroke

neuroradiology, and interventional neuroradiology divisions.

By providing a shared framework, the center will ensure

that the latest advances in neurovascular diagnoses,

treatments, and patient care are readily shared across these

programs, while facilitating collaboration among clinical and

basic science investigators in these areas.

In addition, the new center will support ongoing training and

education initiatives in neurovascular medicine, with fellowships

planned in stroke neurology, interventional neuroradiology, and

vascular interventional neurosurgery.

CERTIFICATION RECOGNIZES COMPREHENSIVE STROKE CENTER, REAFFIRMS ONGOING NEUROVASCULAR RESEARCH

In September 2017, the high-volume stroke units at

NYU Langone’s Tisch Hospital in Manhattan and NYU Langone

Hospital–Brooklyn were, for the first time, certified as a single

Comprehensive Stroke Center by the Joint Commission. In its

assessment, the commission praised the rapid, seamless

integration of the two campuses, and the center’s emphasis on

the entire stroke care continuum, enabled by the center’s

excellent rehabilitation facilities and innovative research

initiatives. The joint certification underscores NYU Langone’s

commitment to providing cutting-edge neurovascular care for

a large—and expanding—patient population.

In one avenue of research at the center, investigators are

pursuing strategies to help restore function after a stroke, such

as improving hand and arm function by promoting connections

between the two sides of the brain. Additional center protocols

showing promise for stroke patients include the use of music

to create enriched environments, tailored treatment to facilitate

movement and reduce muscle stiffness, and the creation of

personalized rehabilitation protocols based on data feedback

from interactive devices.

“These approaches represent the new standards of post-stroke

care at work in our center,” notes Koto Ishida, MD, assistant

professor of neurology and director of NYU Langone’s Stroke

Service. “Our certification was a chance to look back at our

growth and accomplishments over the last few years and

redouble our research efforts—with our newly integrated team—

to offer new hope for stroke patients.”

Over 1,100VASCULAR PROCEDURES PERFORMED IN THE PAST YEAR

55 % ReductionIN MEDIAN TIME TO tPA IN THE PAST 7 YEARS


Gamma Knife Radiosurgery Delivers Precision Treatment for Brain Tumors and AVMs

Two recent, very different, very complex cases highlight the utility and efficacy of Gamma Knife radiosurgery for brain tumors and arteriovenous malformations.

GAMMA KNIFE

PRECISION RADIOSURGERY COMBINES WITH GENETICALLY TAILORED DRUGS TO CONTROL CANCER

For cancer patients with brain metastases, conventional whole-brain radiation treatment can result in a host of side effects, including memory impairment, fatigue, hair loss, and reduced independence. With the use of Gamma Knife radio surgery, a more targeted effective alternative, notes Douglas S.Kondziolka, MD, the Gray Family Professor of Neurosurgery, professor of radiation oncology, vice chair of Clinical Research in the Department of Neurosurgery, and director of NYU Langone’s Gamma Knife program, patients can be spared these side effects.

Paradoxically, as systemic treatments improve for various cancers, the incidence of metastases in the brain—less affected by systemic therapies—is increasing, making their targeted treatment more important than ever. In 2017, Dr. Kondziolka and colleagues at NYU Langone published a study in the Journal of Neurosurgery demonstrating tumor control rates near 100 percent for brain tumors less than a centimeter in diameter that had been targeted early. “As the evidence continues to mount and prove the Gamma Knife’s efficacy, more oncologists are surveilling patients and finding brain tumors earlier—enabling us to be more proactive and to avoid neurological symptoms,” says Dr. Kondziolka.

A recent patient provides a case in point. Referred to Dr. Kondziolka for consultation, the patient had been previously diagnosed with, and treated for, lung cancer, which involved a mutation that made it susceptible to a targeted drug treatment. In addition to the lung cancer, the patient was found to have 15 small tumors in his brain. “We used precisely targeted Gamma Knife radiosurgery to destroy all 15 tumors, and the patient responded beautifully,” notes Dr. Kondziolka.

During the next year, the patient’s lung cancer improved with drug treatment, and quarterly brain scans showed he was clear of brain tumors. A year after the initial Gamma Knife treatment, however, 13 new brain tumors appeared. “With quarterly surveillance, we spotted them early, when they were still small,” says Dr. Kondziolka, “and at that size, we expected these new tumors to respond very well again.”

As before, Dr. Kondziolka’s team treated the 13 tumors with the Gamma Knife and the patient continued on drug therapy. A year later—two years after the patient’s first brain cancer diagnosis—he remains active and without symptoms, which Dr. Kondziolka attributes in part to the effective genetically targeted lung cancer treatment and in part to the early detection and successful radiosurgery of the brain tumors that did occur. Although tumors could recur, notes Dr. Kondziolka, that has not happened, and the patient maintains perfect neurological function. “Patients like these are breaking the ‘rules’ of cancer,” he adds.

GAMMA KNIFE REGISTRY ENABLES RESEARCH, ENHANCES CARE

Having registered several

thousand patients, NYU Langone

physicians are the leading

contributors to the American

Association of Neurological

Surgeons/ASTRO national

radiosurgery registry, which

maintains detailed information on

patient conditions, histories, and

outcomes. The information is

available on demand to

NYU Langone physicians, and to

physicians across the country, to

inform care and improve patient

diagnosis and treatment.

The greatest value of the registry

is that the outcome data are

always available; a physician

studying the effectiveness of

radiosurgery for a specific

condition can retrieve those cases

quickly. “Keeping the registry

current involves significant time

and effort, with information

required prospectively on each

patient, every day—with the payoff

being complete data access,”

notes Dr. Kondziolka. As the

registry continues to evolve, its

applications are expected to

expand, guiding surgeons toward

enhanced outcomes as part

of a data-driven approach to

patient care.


GAMMA KNIFE SURGERY FOR AN “UNRESECTABLE” AVM

Treatment of arteriovenous malformations (AVMs) in the brain -

stem always presents a clinical challenge because of the region’s

many critical neurologic functions, but in many cases the

Gamma Knife has proved to be a critical tool in their treatment.

In 2017, the NYU Langone radiosurgery team co-authored a

series of publications—two that appeared in the journal

Neurosurgery and a third in World Neurosurgery—highlighting

multicenter studies of Gamma Knife surgery outcomes for AVMs

in the brain, all affirming the surgery’s efficacy for patients less

suitable for resection or curative embolization.

For some patients with highly complex AVMs, the Gamma Knife

provides a surgical option when traditional resection is ruled out.

One such patient presented to Dr. Kondziolka more than five

years ago with a congenital brainstem AVM so complex, it was

thought to be untreatable. The whole brainstem looked like a

massive collection of blood vessels, requiring a very thoughtful

treatment approach. “At that time, nobody knew what to do—you

could never have cut it out,” notes Dr. Kondziolka. “Because of

its complexity, we decided not to touch this AVM.”

Several years later, that plan became untenable, when the AVM

hemorrhaged and caused a stroke. “At this point, we had to do

something,” continues Dr. Kondziolka. “I talked to colleagues

around the country, and we decided to attempt a very careful

treatment approach using the Gamma Knife.”

In collaboration with NYU Langone’s neuroradiologists, the team

employed diffusion tensor imaging during the procedure to

visualize the brainstem nerve fiber tracts. Then, to avoid injuring

the nerve fibers, they used a small amount of Gamma Knife

energy to target the AVM. “It was a very precise use of the

technology,” notes Dr. Kondziolka.

A year later, the patient is doing well. “The AVM looks like it’s

closing off, the patient’s motor tracts are fine, and he is an active

young man,” says Dr. Kondziolka. “This patient experienced an

excellent outcome for what was thought to be an unresectable

condition,” he says. “We’re seeing more and more cases where

Gamma Knife changes the trajectory of treatment, ultimately

delivering a positive outcome.”

Presurgical diffusion tractography of the left corticospinal tract in the brainstem, showing a large AVM centered in the mid and rostral pons.

Six months after treatment, the vascular mass has reduced in size and the tract remains intact and in stable position within the central pons.


NEURO-OPHTHALMOLOGY

Vision-Based Diagnostics Expand Clinicians’ Vantage into Neurological Conditions

Expanded applications of optical coherence tomography (OCT)—delivering 1,000 times the resolution of MRI—and other vision-based diagnostic tools are elucidating the markers and mechanisms behind complex neurological conditions.

OCT SCANS OF RETINAL NERVE FIBER LAYER SHOW PROMISE FOR EARLY DIAGNOSIS OF MS-RELATED EYE DAMAGE

Although the optic nerve is involved in the manifestation of multiple sclerosis (MS) for most patients—in a quarter of them, acute optic neuritis is its initial manifestation—the optic nerve remains absent from the condition’s diagnostic criteria. Bolstered by new NYU Langone Health–led research with an international reach, clinicians can now turn to OCT scans of the retinal nerve fiber layer to identify how the optic nerve can add to MS diagnostic criteria.

A high-resolution, noninvasive ocular imaging method, OCT allows clinicians to spot microscopic changes in nerve fiber layer thickness that MRIs can’t detect. “With OCT scans, we have an effective structural measure for this important dimension of MS,” notes Laura J. Balcer, MD, professor of neurology, ophthalmology, and population health and vice chair of the Department of Neurology. Furthermore, Dr. Balcer notes, OCT can identify even very subtle optic nerve damage that occurs before there is any subjective change in vision. This can be useful for early diagnosis for the large cohort of MS patients whose condition begins with acute optic neuritis.

Dr. Balcer and a team of investigators conducted an extensive analysis of OCT scan data from MS patients and from individuals without MS and determined that a five-micron reduction in the thickness of the retinal nerve fiber layer is enough to indicate MS-related nerve damage. In conjunction with the

International Multiple Sclerosis Visual System Consortium (IMSVISUAL), researchers are now using these results, published in late 2017, to lead the effort to expand studies of OCT-visualized optic nerve lesions as a potential diagnostic marker for MS. Dr. Balcer, a co-director of IMSVISUAL, and Steven L. Galetta, MD, the Philip K. Moskowitz, MD Professor and Chair of Neurology and professor of neurology and ophthalmology, co-wrote an editorial published in 2017 in Multiple Sclerosis Journal, advocating for

the inclusion of the optic nerve in the international MS diagnosis criteria.

OCT imaging technology affects the MS field beyond its use in measuring acute optic nerve damage from MS, adds Dr. Balcer. Since optic nerve thinning has been found to reflect the overall impact of MS on the central nervous system, she speculates that OCT retinal scans could one day be used as one of several measures to track overall progression of the disease, including therapeutic response.

Steven L. Galetta, MD, and Laura J. Balcer, MD


EXPANDING THE USE OF RAPID EYE MOVEMENTS AS A CLUE TO NEUROLOGICAL ILLNESS

With the help of the EyeLink high-speed camera, investigators in

the Eye Movement Testing Lab are seeking a new understanding

of the eye movement abnormalities associated with a variety of

neurological disorders—insights that could lead to enhanced

diagnostic and treatment approaches.

NYU Langone researchers have made important connections

between eye movements and concussion over the past several

years, finding that concussion produces an increased

intersaccadic interval—the time it takes the eye to prepare for

rapid jumps from one focal point to another—explaining slower

performance on rapid number-reading tests. “Two factors that

may play a role in this increased intersaccadic interval in

concussion are prolongation of the latency period—the time that

the brain needs to prepare to make fine eye movements—and

neurocognitive dysfunction,” says Janet C. Rucker, MD, the

Bernard A. and Charlotte Marden Professor of Neurology,

professor of ophthalmology, and Chief of the Division of

Neuro-Ophthalmology.

Dr. Rucker leads the Eye Movement Testing Lab in partnership

with two physicians at NYU Langone’s Rusk Rehabilitation:

John-Ross Rizzo, MD, assistant professor of rehabilitation

medicine and neurology, and Todd E. Hudson, PhD, research

assistant professor of rehabilitation medicine. Together, these

investigators are evaluating how attention and cognition affect

the scores of concussed patients. “Once we understand

concussion’s activity in the brain, we hope to find ways to predict

recovery and develop therapies,” Dr. Rucker says.

Separately, investigators are working on EyeLink applications

to enhance diagnosis and therapeutic intervention in multiple

sclerosis (MS) and Parkinson’s disease. The information

gained from detailed analysis of nystagmus and internuclear

ophthalmo plegia may help investigators to advance therapeutic

options for MS, and rapid number-reading and picture-naming

tests are being studied as quick screening tools for vision

problems in MS. In Parkinson’s, eye movement analysis is being

used to confirm diagnosis of atypical Parkinson’s disorders such

as progressive supranuclear palsy and multiple system atrophy.

“It’s hard to name a neurological disease that doesn’t have

the capacity to affect eye movements in some way,” notes

Dr. Rucker. “Eye movement recording technology can help us

establish a more accurate diagnosis and evaluate potentially

more efficacious treatments.”

ASSESSING CONCUSSION-RELATED BRAIN DAMAGE WITH VISUAL SCREENS

Researchers are also investigating the use of OCT and other vision-based testing to measure function in the setting of concussion and related neurological damage. The Division of Neuro-Ophthalmology plays a leadership role in NYU Langone’s Concussion Center, where research on the use of a rapid number-naming test and laboratory-based eye tracking is aiding in the sideline diagnosis and assessment of sports-related concussion.

The division is spearheading a study of OCT in active and retired contact-sport athletes. At the same time, NYU Langone is an enrolling site for a Boston University–led, National Institutes of Health–funded study of potential markers for chronic

traumatic encephalopathy among retired football players and individuals with little or no contact sport exposure.

In a separate study, published in 2017 in the Journal of Neuro-Ophthalmology, division researchers and colleagues from the Illinois College of Optometry found that average retinal nerve thickness among collision-sport athletes was reduced relative to controls. The difference was especially pronounced among the study’s subgroup of boxers, who had an average nerve thickness reduction of almost 11 microns compared with the control group. “This study suggests that OCT may identify athletes who have had significant repetitive traumatic brain injury,” notes Dr. Galetta. A test of the same subjects’ low-contrast letter acuity also found significant differences between the athletes and controls, with boxers

again showing the greatest disparity. Further investigations are under way to better determine the relationship between retinal nerve fiber loss and traumatic brain injury.

“We were fortunate to be early adopters of OCT and low-contrast visual tests in MS, over a decade ago,” says Dr. Galetta. “Now we’re taking the paradigms we learned in MS and applying them to traumatic brain injury, studying visual tests and OCT as outcome measures in other neurological conditions.”


SPINE

Complex Case: Intramedullary Cavernoma Calls for Intervention—but Carries Risks

For a 29-year-old patient presenting with a rare and risky intramedullary cavernoma, the use of advanced diffusion tensor imaging (DTI), pioneered at NYU Langone for spinal surgery, proved essential to a successful resection—and restored quality of life.

When Anthony K. Frempong-Boadu, MD,

associate professor of neurosurgery and

director of the Division of Spinal Surgery,

evaluated the patient’s symptoms and

progressing condition, he quickly saw the

dilemma: Resection of such a complex

tumor required the use of a leading-edge,

highly precise imaging technique that had

only a limited track record—but postponing

the surgery was not an option. The

debilitating effects of the intradural

intramedullary cavernoma had become

increasingly apparent in the year since it

was first diagnosed, and they would only

worsen as the tumor grew. “It was clear that

this tumor needed to be managed

surgically,” says Dr. Frempong-Boadu.

However, such a resection carried

formidable risks. Intramedullary tumors,

which account for just 2 to 4 percent of all

intrinsic central nervous system tumors,

often permeate the surrounding tissues

after arising from the cells of the spinal

cord. Resection of this tumor would require

a myelotomy—dissection of the spinal cord

at the midline—to achieve access, a surgery

with a high risk of permanent morbidity,

damage to paraspinal structures,

cerebrospinal fluid leak, central nervous

system infection, and significant

neurological injury, including paraplegia.

The tumor was densely adhered to

surrounding nerve tissue, increasing the

likelihood of surgical complications.

Other leading tertiary centers had been

reluctant to perform the operation.

ADVANCED NEURAL IMAGES PROVIDE A ROAD MAP FOR RESECTION

With Dr. Frempong-Boadu’s successful

DTI application two years earlier,

NYU Langone had become the nation’s only

center to use real-time intraoperative

functional data during spinal surgery. In this

case, use of this approach—which employs

multiple high-information MRI scans of

the water diffusion rates across nerve

membranes to map the exact location of a

patient’s nerve tracts—was critical to

keeping the patient neurologically intact as

the tumor was resected.

“With DTI, combined with Surgical Theater’s

three-dimensional virtual imagery of the

surgical site, we could visualize exactly

where the motor tracts of the patient’s

spinal cord and all other relevant structures

were at all times, so we could go in and

confidently remove the tumor,” says

Dr. Frempong-Boadu.

Anthony K. Frempong-Boadu, MD


A MULTIDISCIPLINARY TEAM EFFORT AUGMENTS ADVANCED IMAGING

With the full array of spinal imaging

techniques at work in the operating room,

the surgical team began with a

decompressive osteoplastic laminectomy

of the third and fourth thoracic vertebrae.

They then located the tumor via ultrasound

and confirmed the location using an

intraoperative CT scan, intraoperative

navigation, and Surgical Theater’s virtual

imagery of the site. The dura was opened

and retracted, the arachnoid layer was

dissected free and opened, and the dorsal

root entry zone was identified using

intraoperative navigation. The surgeons

performed a myelotomy and isolated the

tumor, carefully dissecting it free from

the underlying neural tissue, utilizing both

microscope-integrated stereotactic

navigation and three-dimensional

visualization. After removal of the tumor,

the dura was closed and the vertebrae

were reconstructed.

“The imaging precisely outlined the tumor

in three dimensions, so I knew when I

needed to back off and when I could press

ahead right to its margin,” explains

Dr. Frempong-Boadu. “In these procedures,

our goal is to get the greatest amount of

resection possible with the least amount of

functional decline.”

BEYOND TUMORS: EXTENDING THE NEURAL MAPS’ REACH

Although neurophysiological monitoring

indicated some reduction in left leg sensory

and motor signals during this patient’s

operation, says Dr. Frempong-Boadu, the

procedure concluded with the intra-

medullary cavernoma completely resected

and no motor impairment beyond a very

slight limp. “A half year later, the patient is

doing really well—an incredible outcome

given the complexity of his tumor,” he adds.

Since assembly of the neural maps is itself

a highly complex process, use of the maps

is currently limited to the most complex,

high-acuity spine tumor cases. The

neurosurgery and neuroradiology groups

are working on new automation processes

to streamline image acquisition and nerve

map construction, to potentially extend the

technology’s application to cervical

spondylosis, myelopathy, and other

spinal conditions. “The applicability of this

mapping to spinal disease extends well

beyond its current use,” says Dr. Frempong-

Boadu. “If we can accomplish that, it will be

another huge step forward.”

Three-dimensional imaging of the intradural intramedullary cavernoma


The Pursuit of New Alzheimer’s Pathways, Fueled by Promising Research

The Center for Cognitive Neurology is working to unravel the mechanisms behind Alzheimer’s disease and other neurocognitive disorders, while forging new pathways toward transformative treatment and prevention modalities.

COGNITIVE NEUROLOGY

PROMISING IMMUNOTHERAPIES MOVE CLOSER TO HUMAN TESTING

In 2017, the Center for Cognitive Neurology conducted several groundbreaking studies that could give rise to novel Alzheimer’s disease immunotherapies. “We now know that Alzheimer’s is driven by many pathways, which can vary from patient to patient,” notes Thomas M. Wisniewski, MD, the Gerald J. and Dorothy R. Friedman

Professor of Neurology, professor of pathology and psychiatry, and director of the center. “As our understanding of Alzheimer’s improves, we’re testing many promising therapeutic interventions.”

One such intervention involves conformational monoclonal antibodies, the only agents known to target neurotoxic oligomers—clusters of misfolded proteins associated with both amyloid-beta and tau, and with neurodegenerative diseases including Parkinson’s. In an article in

Scientific Reports in 2017, NYU Langone Health investigators described how a protein fragment derived from the rare disease British amyloidosis can be used to prime antibodies to attack the beta-sheet structure common across various oligomers. In the near future, center researchers hope to move this unified treatment approach, successful in animal studies, to human trials.

In another 2017 animal study, published in The Journal of Neuroscience,

Allal Boutajangout, PhD, and Thomas M. Wisniewski, MD


center investigators demonstrated the efficacy of the NYU Langone–developed immunotherapy drug Class B CpG ODN in reducing cerebral amyloid angiopathy, another key element of Alzheimer’s pathology, with accompanying short-term memory improvements. This drug, previously found to enhance clearance of amyloid-beta and tau in animals, boosts activity of microglia—the primary immune cells in the brain—by stimulating Toll-like receptor 9. The center hopes to commence phase I human trials within the next two years.

Another 2017 study published in Scientific Reports extended NYU Langone’s groundbreaking investigations of interaction between amyloid-beta and apolipoprotein E (apoE)—the brain’s main lipid-carrying protein, which can accelerate accumulation of amyloid-beta in the brain. In the study, a novel peptoid developed by NYU Langone researchers was highly effective at preventing amyloid-beta from binding with apoE, including apoE4, the most neurotoxic apoE variant.

In a fourth study, published in early 2017 in Current Alzheimer Research, center researchers showed that human umbilical cord stem cells injected into the carotid arteries of transgenic mice can cross the blood–brain barrier and reduce Alzheimer’s-related pathology, offering

another possible dementia-prevention approach. Meanwhile, the center continues its phase III clinical trials of the monoclonal antibody aducanumab, which appears to clear amyloid plaque from the brains of individuals with early Alzheimer’s.

UNRAVELING THE BIOLOGY OF ALZHEIMER’S DISEASE

As new therapies are pursued, the center continues to probe the biology underlying Alzheimer’s. In a seminal 2017 study published in Acta Neuropathologica, researchers applied proteomics to analyze amyloid plaques associated with rapidly progressive Alzheimer’s disease. The researchers found that the plaques contained significantly higher levels of neuronal proteins and lower levels of astrocytic proteins compared with standard Alzheimer’s, opening a new research pathway. The center will pursue the pathway with support from a five-year, $3.9 million R01 grant awarded by the National Institutes of Health (NIH) in 2017. “This study was critically dependent on the proteomic core that we have here at NYU Langone, one of the best in the world,” says Dr. Wisniewski.

Another animal study, led by Martin Sadowski, MD, PhD, associate professor of neurology, psychiatry, and biochemistry and molecular

pharmacology, adds a key piece to the apoE puzzle. The 2017 study, published in Molecular Degeneration, found that transgenic mice with the apoE4 gene variant—the greatest genetic risk factor for late-onset Alzheimer’s—showed the most robust stimulation of microglia and the greatest reduction in amyloid plaques when injected with the experimental anti-amyloid-beta antibody 10D5. “This offers hope that Alzheimer’s vaccines may work better in human apoE4 carriers, even though they tend to get Alzheimer’s at a younger age and have more amyloid buildup than people without the variant,” says Dr. Sadowski. He and his team are engaged in further study of this phenomenon through two NIH grants.

NEW INSIGHTS REVEAL TRAUMATIC BRAIN INJURY PATHOLOGY

A milestone discovery by Center for

Cognitive Neurology researchers

could open a new avenue to potential

therapies to mitigate traumatic brain

injury (TBI) and prevent chronic

traumatic encephalopathy. The

research, led by Dr. Wisniewski and

published in Acta Neuropathologica Communications in 2017, revealed

that normal prion proteins are a

mediator of TBI, serving as receptors

for the tau oligomers that form in the

injury’s aftermath. “We already have

preexisting antibodies that target the

prion protein,” notes Dr. Wisniewski.

“Now, our lab can begin testing these

drugs, in hopes of reducing trauma-

related brain damage.”

$27.9 M IN NIH GRANT RESEARCH FUNDING AWARDED SINCE 2015

with

$8.3 M AWARDED IN 2017


Patients with Movement Disorder Symptoms Find New Relief in Neuromodulation

Clinical trials under way at NYU Langone Health’s Center for Neuromodulation are expanding the availability and applications of deep brain stimulation (DBS) techniques, MRI-guided ultrasound approaches, and other innovations—bringing benefits to a broad range of patients.

Alon Y. Mogilner, MD, PhD, and Michael H. Pourfar, MD

NEUROMODULATION

NYU LANGONE CHARTS NEW TERRITORY WITH SECOND-GENERATION DBS DEVICES

Medtronic’s DBS device has been the only FDA-approved DBS technology for more than 20 years, but the field is now expanding with the recent approval of Abbott’s DBS system, as well as an ongoing clinical trial utilizing a DBS system manufactured by Boston Scientific. Both new devices offer more nuanced distribution of electrical stimulation, which may prove advantageous in some cases, says Michael H. Pourfar, MD, assistant professor of neurosurgery and neurology and co-director of NYU Langone’s Center for Neuromodulation—the only facility in New York with extensive experience with all three devices.

All three technologies have their strengths, says the center’s other co-director, Alon Y. Mogilner, MD, PhD, associate professor of neurosurgery and anesthesiology. “At the moment, the Medtronic device is the only MRI-compatible system, which can benefit certain patients,” he notes. “In other instances, the alternate approaches broaden the therapeutic window by letting us more effectively troubleshoot side effects, such as impaired speech or balance.”

Clinicians used to grapple with simply whether someone was a candidate for DBS. Now, observes Dr. Mogilner, “we’re having increasingly sophisticated conversations about which DBS system to use and which targets to select within that system.”

ADDING TO THE NEUROMODULATION ARSENAL: FOCUSED ULTRASOUND

The center is investigating other neuromodulation treatment modalities, including MRI-guided focused ultrasound, which noninvasively targets precise areas of brain tissue to alleviate tremor. Under MRI guidance, the ultrasound device first heats mapped tissue, producing a temporary effect so clinicians can confirm that ablating the targeted area will improve symptoms without problematic side effects. Then the ultrasound beam is intensified to destroy the selected brain cells associated with the tremor.


PIONEERING GAMMA KNIFE SURGERY AS TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER

Gamma Knife radiosurgery has emerged alongside FDA-

approved DBS as a novel treatment for obsessive-compulsive

disorder (OCD). The approach uses radiation to create a

pinpoint lesion in well-identified bilateral targets in the anterior

limb of the internal capsule of the brain, between the thalamus

and the frontal lobe, known to be involved in OCD.

“We are one of the few institutions in the world offering Gamma

Knife radiosurgery as an OCD treatment modality,” says

Douglas S. Kondziolka, MD, the Gray Family Professor of

Neurosurgery, professor of radiation oncology, vice chair for

Clinical Research in the Department of Neurosurgery, and

director of NYU Langone’s Gamma Knife program.

Dr. Kondziolka’s team is conducting a national study on

Gamma Knife OCD outcomes; though investigators are seeing

positive anecdotal results, the brain requires time to rewire

itself, so it can take years to produce the full treatment benefit.

“This approach can moderate symptoms for the most

debilitated OCD patients,” notes Dr. Kondziolka.

“Following treatment, patients score better on measures of

thought resistance and behavior avoidance; the goal is to

reduce the intrusive thoughts and compulsive rituals that so

dominate their lives,” Dr. Kondziolka adds.

Joshua S. Silverman, MD, PhD, and Douglas S. Kondziolka, MD

175 +DBS PROCEDURES

performed in 2017

“Since this nonsurgical approach requires little or no anesthesia, it can benefit patients who are too elderly or ill for DBS,” notes Dr. Pourfar. “Unlike with DBS, there’s no implanted hardware and no need for repeated visits to adjust the programming.” Although focused ultrasound is currently used only for tremors, the center’s clinicians are working with NYU Langone neuroradiologists to identify possible ablation targets for symptoms such as stiffness or slowed movement. The system will be fully operational in early 2018, and clinicians are hoping to begin clinical trials soon after.

NEW FRONTIERS IN DBS FOR TOURETTE’S AND REFRACTORY PARKINSON’S

DBS can also offer hope for those with treatment-resistant Tourette’s syndrome. The center’s clinicians continue to pioneer this off-label application with

groundbreaking research, including a recent study of 13 NYU Langone patients who underwent thalamic DBS for severe Tourette’s, the largest such series in the United States. Led by Dr. Mogilner and Dr. Pourfar and published in April 2017 in the Journal of Neurosurgery, the study found that after the DBS procedure, the patients’ tic severity decreased by 50 percent, on average, by the time of their last postsurgery follow-up.

“While results can vary, DBS has been life-changing for some Tourette’s patients,” says Dr. Mogilner. “We’re all working to gain a better understanding of this therapeutic approach, leading, we hope, to FDA approval of DBS as a Tourette’s treatment.”

Center researchers continue to mine their own data in combination with the national Tourette’s database at the University of Florida in order to refine the target brain regions and stimulation

parameters used to treat the condition. Clinicians have also been refining their use of rescue leads—additional electrode clusters implanted in Parkinson’s patients who continue to experience significant tremors or dyskinesia after initial bilateral DBS lead implantation. “We’ve found that adding the third electrode provides benefit to a number of patients,” says Dr. Mogilner, who is leading the preparation of an article on the center’s rescue lead patient series. “This is an area where the field will continue to improve,” he notes.


SELECT PUBLICATIONS: NEUROLOGY

Abou-Khalil B, Afawi Z, Allen AS, Bautista JF, Bellows ST, Berkovic SF, Bluvstein J, Burgess R, Cascino G, Cops EJ, Cossette P, Cristofaro S, Crompton DE, Delanty N, Devinsky O, Dlugos D, Epstein MP, Fountain NB, Freyer C, Garry SI, Geller EB, Glauser T, Glynn S, Goldberg-Stern H, Goldstein DB, Gravel M, Haas K, Haut S, Heinzen EL, Kirsch HE, Kivity S, Knowlton R, Korczyn AD, Kossoff E, Kuzniecky R, Loeb R, Lowenstein DH, Marson AG, McCormack M, McKenna K, Mefford HC, Motika P, Mullen SA, O’Brien TJ, Ottman R, Paolicchi J, Parent JM, Paterson S, Petrovski S, Pickrell WO, Poduri A, Rees MI, Sadleir LG, Scheffer IE, Shih J, Singh R, Sirven J, Smith M, Smith PEM, Thio LL, Thomas RH, Venkat A, Vining E, Von Allmen G, Weisenberg J, Widdess-Walsh P, Winawer MR, Epi4K Consortium. Phenotypic analysis of 303 multiplex families with common epilepsies. Brain: A Journal of Neurology. August 2017; 140(8): 2144–2156.

Adams J, Alipio-Jocson V, Inoyama K, Bartlett V, Sandhu S, Oso J, Barry JJ, Loring DW, Meador KJ. Methylphenidate, cognition, and epilepsy: a 1-month open-label trial. Epilepsia. December 2017; 58(12): 2124–2132.

Allen AS, Bellows ST, Berkovic SF, Bridgers J, Burgess R, Cavalleri G, Chung S-K, Cossette P, Delanty N, Dlugos D, Epstein MP, Freyer C, Goldstein DB, Heinzen EL, Hildebrand MS, Johnson MR, Kuzniecky R, Lowenstein DH, Marson AG, Mayeux R, Mebane C, Mefford HC, O’Brien TJ, Ottman R, Petrou S, Petrovski S, Pickrell WO, Poduri A, Radtke RA, Rees MI, Regan BM, Ren Z, Scheffer IE, Sills GJ, Thomas RH, Wang Q, Abou-Khalil B, Alldredge BK, Amrom D, Andermann E, Andermann F, Bautista JF, Berkovic SF, Bluvstein J, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Freyer C, Friedman D, Geller EB, Glauser T, Glynn S, Haas K, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Sadleir LG, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Shinnar S, Singh RK, Sirven J, Smith MC, Sullivan J, Thio LL, Venkat A, Vining EPG, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR, Epi4k Consortium, Epilepsy Phenome-Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. The Lancet Neurology. February 2017; 16(2): 135–143.

Allen AS, Berkovic SF, Bridgers J, Cossette P, Dlugos D, Epstein MP, Glauser T, Goldstein DB, Heinzen EL, Jiang Y, Johnson MR, Kuzniecky R, Lowenstein DH, Marson AG, Mefford HC, O’Brien TJ, Ottman R, Petrou S, Petrovski S, Poduri A, Ren Z, Scheffer IE, Sherr E, Wang Q, Balling R, Barisic N, Baulac S, Caglayan H, Craiu D, De Jonghe P, Depienne C, Guerrini R, Helbig I, Hjalgrim H, Hoffman-Zacharska D, Jahn J, Klein KM, Koeleman B, Komarek V, Krause R, Leguern E, Lehesjoki A-E, Lemke JR, Lerche H, Linnankivi T, Marini C, May P, Moller RS, Muhle H, Pal D, Palotie A, Rosenow F, Selmer K, Serratosa JM, Sisodiya S, Stephani U, Sterbova K, Striano P, Suls A, Talvik T, Von Spiczak S, Weber Y, Weckhuysen S, Zara F, Abou-Khalil B, Alldredge BK, Amrom D, Andermann E, Andermann F, Bautista JF, Bluvstein J, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Fiol ME, Fountain NB, French J, Friedman D, Haas K, Haut SR, Hayward J, Joshi S, Kanner A, Kirsch HE, Kossoff EH, Kuperman R, McGuire SM, Motika PV, Novotny EJ, Paolicchi JM, Parent J, Park K, Shellhaas RA, Sirven J, Smith MC, Sullivan J, Thio LL, Venkat A, Vining EPG, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. European Journal of Human Genetics. June 2017; 25(7): 894–899.

Al-Louzi O, Sotirchos ES, Vidal-Jordana A, Beh SC, Button J, Ying HS, Balcer LJ, Frohman EM, Saidha S, Calabresi PA, Newsome SD. Characteristics of morphologic macular abnormalities in neuroimmunology practice. Multiple Sclerosis. November 1, 2017; 1352458517741206.

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eicher AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precision Oncology. June 12, 2017; 1: 20.

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. May 12, 2017; 8(45): 79298–79304.

Ashina H, Newman L, Ashina S. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment. Neurological Sciences. December 2017; 38(12): 2089–2093.

Atherton DS, Davis GG, Wright C, Devinsky O, Hesdorffer D. A survey of medical examiner death certification of vignettes on death in epilepsy: gaps in identifying SUDEP. Epilepsy Research. July 2017; 133: 71–75.

Bajaj S, Krismer F, Palma J-A, Wenning GK, Kaufmann H, Poewe W, Seppi K. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: a systematic review and meta-analysis. PLoS One. December 29, 2017; 12(12): e0189897.

Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, LaRocca N, Hudson L, Rudick R. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal. April 2017; 23(5): 704–710.

Bar-Aluma B-E, Efrati O, Kaufmann H, Palma J-A, Norcliffe-Kaufmann L. A controlled trial of inhaled bronchodilators in familial dysautonomia. Lung. December 12, 2017; 1–9. epub ahead of print.

Becker DA, Schiff ND, Becker LB, Holmes MG, Fins JJ, Horowitz JM, Devinsky O. A major miss in prognostication after cardiac arrest: burst suppression and brain healing. Epilepsy & Behavior Case Reports. 2017; 7: 1–5.

Begasse de Dhaem O, Barr WB, Balcer LJ, Galetta SL, Minen MT. Post-traumatic headache: the use of the sport concussion assessment tool (SCAT-3) as a predictor of post-concussion recovery. Journal of Headache and Pain. December 2017; 18(1): 60.

Berg AT, Altalib HH, Devinsky O. Psychiatric and behavioral comorbidities in epilepsy: a critical reappraisal. Epilepsia. July 2017; 58(7): 1123–1130.

Berger KI, Burton BK, Lewis GD, Tarnopolsky M, Harmatz PR, Mitchell JJ, Muschol N, Jones SA, Sutton VR, Pastores GM, Lau H, Sparkes R, Shaywitz AJ. Cardiopulmonary exercise testing reflects improved exercise capacity in response to treatment in Morquio A patients: results of a 52-week pilot study of two different doses of Elosulfase Alfa. JIMD Reports. November 21, 2017. epub ahead of print.

Biaggioni I, Hewitt LA, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurology. May 12, 2017; 17(1): 90.

Bianchi S, Battistella G, Huddleston H, Scharf R, Fleysher L, Rumbach AF, Frucht SJ, Blitzer A, Ozelius LJ, Simonyan K. Phenotype- and genotype-specific structural alterations in spasmodic dysphonia. Movement Disorders. April 2017; 32(4): 560–568.

Blackmon K, Thesen T, Green S, Ben-Avi E, Wang X, Fuchs B, Kuzniecky R, Devinsky O. Focal cortical anomalies and language impairment in 16p11.2 deletion and duplication syndrome. Cerebral Cortex. June 7, 2017; 1–9. epub ahead of print.

Boutajangout A, Noorwali A, Atta H, Wisniewski T. Human umbilical cord stem cell xenografts improve cognitive decline and reduce the amyloid burden in a mouse model of Alzheimer’s disease. Current Alzheimer Research. 2017; 14(1): 104–111.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D’Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Forsch MP, Suva ML, Cahill DP, Getz G, Batchelor TT. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precision Oncology. September 18, 2017; 1: 33.

Burke EA, Frucht SJ, Thompson K, Wolfe LA, Yokoyama T, Bertoni M, Huang Y, Sincan M, Adams DR, Taylor RW, Gahl WA, Toro C, Malicdan MCV. Biallelic mutations in mitochondrial tryptophanyl-tRNA synthetase cause levodopa-responsive infantile-onset Parkinsonism. Clinical Genetics. November 9, 2017. epub ahead of print.

Button J, Al-Louzi O, Lang A, Bhargava P, Newsome SD, Frohman T, Balcer LJ, Frohman EM, Prince J, Calabresi PA, Saidha S. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study. Neurology. February 7, 2017; 88(6): 525–532.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised placebo-controlled, phase 2 trial. The Lancet Neurology. March 2017; 16(3): 189–199.

Chang FCF, Frucht SJ. ICU intensive care unit movement disorder emergencies. In: Hall DA and Barton BR (Eds.) Non-Parkinsonian Movement Disorders. December 27, 2016. John Wiley & Sons, Ltd.

Charvet LE, Dobbs B, Shaw MT, Bikson M, Datta A, Krupp LB. Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial. Multiple Sclerosis Journal. September 1, 2017; 1352458517732842. epub ahead of print.

Charvet L, Shaw M, Dobbs B, Frontario A, Sherman K, Bikson M, Datta A, Krupp L, Zeinapour E, Kasschau M. Remotely supervised transcranial direct current stimulation increases the benefit of at-home cognitive training in multiple sclerosis. Neuromodulation. February 22, 2017. epub ahead of print.

Charvet LE, Shaw M, Frontario A, Langdon D, Krupp LB. Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing. Multiple Sclerosis Journal. March 1, 2017; 1352458517701588. epub ahead of print.

Charvet LE, Yang J, Shaw MT, Sherman K, Haider L, Xu J, Krupp LB. Cognitive function in multiple sclerosis improves with telerehabilitation: results from a randomized controlled trial. PloS One. May 11, 2017; 12(5): e0177177.

Chen H, Dugan P, Chong DJ, Liu A, Doyle W, Friedman D. Application of RNS in refractory epilepsy: targeting insula. Epilepsia Open. September 2017; 2(3): 345–349.

Cheng JY, French JA. Intelligent use of antiepileptic drugs is beneficial to patients. Current Opinion in Neurology. December 22, 2017. epub ahead of print.

Chi AS. Identification of more potent imipridones, a new class of anti-cancer agents. Cell Cycle. August 10, 2017; 16(17): 1566–1567.

Chin JH. Xpert MTB/RIF ultra: the long-awaited game changer for tuberculous meningitis? European Respiratory Journal. October 19, 2017; 50(4): 1701201.

Chin JH, Bhatt JM, Lloyd-Smith AJ. Hypertension—a global neurological problem. Journal of the American Medical Association—Neurology. April 1, 2017; 74(4): 381–382.

Academic Activities


Chin JH, Twinobuhungiro A, Sandhu A, Hootsmans N, Kayima J, Kalyesubula R. Determinants of raised blood pressure in urban Uganda: a community-based case-control study. Ethnicity & Disease. January 19, 2017; 27(1): 15–20.

Chiu AH, De Vries J, O’Kelly CJ, Riina H, McDougall I, Tippett J, Wan M, de Oliveira Manoel AL, Marotta TR. The second-generation eCLIPs Endovascular Clip System: initial experience. Journal of Neurosurgery. March 17, 2017; 1–8. epub ahead of print.

Cho S-M, MacDonald S, Frontera JA. Coxsackie B3/B4-related acute flaccid myelitis. Neurocritical Care. October 2017; 27(2): 259–260.

Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in HeartMate II and HeartWare left ventricular assist devices: a systematic review. Neurocritical Care. August 2017; 27(1): 17–25.

Choi J-H, Wallach AI, Rosales D, Margiewicz SE, Belmont HM, Lucchinetti CF, Minen MT. Clinical reasoning: a 50-year-old woman with SLE and a tumefactive lesion. Neurology. September 19, 2017; 89(12): e140–e145.

Chopra AM, Mehta M, Bismuth J, Shapiro M, Fishbein MC, Bridges AG, Vinters HV. Polymer coating embolism from intravascular medical devices—a clinical literature review. Cardiovascular Pathology. September–October 2017; 30: 45–54.

Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache: The Journal of Head and Face Pain. October 2017; 57(9): 1375–1384.

Cordova C, Chi AS, Chachoua A, Kondziolka D, Silverman JS, Shepherd TM, Jain R, Snuderl M. Osimertinib dose escalation induces regression of progressive EGFR T790M-mutant leptomeningeal lung adenocarcinoma. Journal of Thoracic Oncology. November 2017; 12(11): e188–e190.

Crandall L, Devinsky O. Sudden unexplained death in children. The Lancet Child & Adolescent Health. September 2017; 1(1): 8–9.

Czeisler BM, Claassen J. A novel clinical score to assess seizure risk. Journal of the American Medical Association—Neurology. December 1, 2017; 74(12): 1395–1396.

Dai M, Cohen B, Cho C, Shin S, Yakushin SB. Treatment of the Mal de Debarquement syndrome: a 1-year follow-up. Frontiers in Neurology. May 5, 2017; 8: 175.

Dai W, Selesnick I, Rizzo J-R, Rucker J, Hudson T. A nonlinear generalization of the Savitzky-Golay filter and the quantitative analysis of saccades. Journal of Vision. August 1, 2017; 17(9): 10.

da Silva IRF, Frontera JA. Neurologic complications of acute environmental injuries. Handbook of Clinical Neurology. 2017; 141: 685–704.

da Silva IRF, Frontera JA. Resumption of anticoagulation after intracranial hemorrhage. Current Treatment Options in Neurology. November 2017; 19(11): 39.

da Silva IRF, Frontera JA, Bispo de Filippis AM, do Nascimento OJM. Neurologic complications associated with the Zika virus in Brazilian adults. Journal of the American Medical Association—Neurology. October 1, 2017; 74(10): 1190–1198.

Del Bene VA, Arce Renteria M, Maiman M, Slugh M, Gazzola DM, Nadkarni SS, Barr WB. Increased odds and predictive rates of MMPI-2-RF scale elevations in patients with psychogenic non-epileptic seizures and observed sex differences. Epilepsy & Behavior. July 2017; 72: 43–50.

Delva A, Thakore N, Pioro E, Poesen K, Saunders-Pullman R, Meijer IA, Rucker JC, Kissel JT, Van Damme P. FEWDON-MND syndrome (finger extension weakness and downbeat nystagmus): a novel motor neuron disorder? Muscle & Nerve. December 2017; 56(6): 1164–1168.

Desnick RJ, Barton NW, Furbish S, Grabowski GA, Karlsson S, Kolodny EH, Medin JA, Murray GJ, Mistry PK, Patterson MC, Schiffmann R, Weinreb NJ. Roscoe Owen Brady, MD: remembrances of co-investigators and colleagues. Molecular Genetics and Metabolism. January–February 2017; 120(1–2): 1–7.

Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine. May 25, 2017; 376(21): 699.

Erich G. Anderer, MD, was recognized by the Medical Society of the County of Kings with the 2017 Award of Excellence.

Orrin Devinsky, MD, received the J. Kiffin Penry Excellence in Epilepsy Care Award from the American Epilepsy Society.

David H. Harter, MD, was appointed president elect of the New York State Neurosurgical Society.

Douglas S. Kondziolka, MD, was appointed treasurer of the American Academy of Neurological Surgery.

Lauren B. Krupp, MD, was appointed chair of the International Multiple Sclerosis Cognition Society steering committee.

Mia T. Minen, MD, MPH, was appointed chair of the Emergency Medicine, Inpatient and Refractory Section of the American Headache Society.

James L. Stone, MD, was chosen as a consultant for the National Aeronautics and Space Administration.

Blanca Vazquez, MD, was appointed chair of the Professional Advisory Board of the Epilepsy Foundation of Metropolitan New York.

Thomas M. Wisniewski, MD, was appointed to the board of directors of the New York City chapter of the Alzheimer’s Association.

AWARDS & RECOGNITION: NEUROLOGY & NEUROSURGERY

Allal Boutajangout, PhD, was a selected keynote speaker at the 15th European Neurology Congress in London, England.

Leigh E. Charvet, PhD, was a selected keynote speaker at the 2017 NYC Neuromodulation Conference in New York, New York.

Horacio Kaufmann, MD, was a selected keynote speaker at the 28th International Symposium on the Autonomic Nervous System in Clearwater, Florida.

John G. Golfinos, MD, was an honored guest speaker at “The Reality in Virtual Reality: A Conversation with Practitioners,” an Enterprise Forum in New York, New York.

Chandranath Sen, MD, served as a program moderator at the 27th Annual Meeting of the North American Skull Base Society in New Orleans, Louisiana, and at the annual Association of Neurological Surgeons meeting in Los Angeles, California.

SELECT CONFERENCE HIGHLIGHTS: NEUROLOGY & NEUROSURGERY


Devinsky O, Friedman D, Cheng JY, Moffatt E, Kim A, Tseng ZH. Underestimation of sudden deaths among patients with seizures and epilepsy. Neurology. August 29, 2017; 89(9): 878–879.

Doumlele K, Friedman D, Buchhalter J, Donner EJ, Louik J, Devinsky O. Sudden unexpected death in epilepsy among patients with benign childhood epilepsy with centrotemporal spikes. Journal of the American Medical Association—Neurology. June 1, 2017; 74(6): 645–649.

Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X, Shao Y, Safar JG, Ueberheide B, Wisniewski T. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathologica. June 2017; 133(6): 933–954.

Drummond E, Nayak S, Ueberheide B, Wisniewski T. Localized proteomics of individual neurons isolated from formalin-fixed, paraffin-embedded tissue sections using laser capture microdissection. Current Proteomic Approaches Applied to Brain Function. June 28, 2017; 289–301. epub ahead of print.

Drummond E, Wisniewski T. The use of localized proteomics to identify the drivers of Alzheimer’s disease pathogenesis. Neural Regeneration Research. June 2017; 12(6): 912–913.

Dugan P, Carlson C, Jette N, Wiebe S, Bunch M, Kuzniecky R, French J. Derivation and initial validation of a surgical grading scale for the preliminary evaluation of adult patients with drug-resistant focal epilepsy. Epilepsia. May 2017; 58(5): 792–800.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H. Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. International Journal of Cancer. December 1, 2017; 141(11): 2348–2358.

Fara MG, Chancellor B, Lord AS, Lewis A. Controversies in cardiopulmonary death. Journal of Clinical Ethics. Summer 2017; 28(2): 97–101.

Fernandez D, Fara MG, Biary R, Hoffman RS, Vassallo S, Balcer L, Torres D. Clinical reasoning: a 27-year-old man with unsteady gait. Neurology. September 5, 2017; 89(10): e120–e123.

Fiorenzato E, Weis L, Seppi K, Onofrj M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W, Krismer F, Wenning G, Antonini A, Biundo R. Brain structural profile of multiple system atrophy patients with cognitive impairment. Journal of Neural Transmission. March 2017; 124(3): 293–302.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr., Forsgren L, French JA, Hesdorffer DC, Lee B-I, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. How long for epilepsy remission in the ILAE definition? Epilepsia. August 2017; 58(8): 1486–1487.

Fisher RS, Cross JH, D’Souza C, French JA, Haut S, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Korey SR, Purpura DP, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian EM, Zuberi SM. Response to the numbering of seizure types. Epilepsia. July 5, 2017; 58: 1300–1301.

Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian EM, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. April 2017; 58(4): 531–542.

Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Zuberi SM. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. April 2017; 58(4): 522–530.

French J, Friedman D. The evolving landscape of epilepsy neuropathology. The Lancet Neurology. November 29, 2017; S1474-4422(17)30429-5. epub ahead of print.

French JA. Withdrawal of antiepileptic drugs: an individualized approach. The Lancet Neurology. July 2017; 16(7): 493–494.

Frontera JA, Provencio JJ, Sehba FA, McIntyre TM, Nowacki AS, Gordon E, Weimer JM, Aledort L. The role of platelet activation and inflammation in early brain injury following subarachnoid hemorrhage. Neurocritical Care. February 2017; 26(1): 48–57.

Fureman BE, Friedman D, Baulac M, Glauser T, Moreno J, Dixon-Salazar T, Bagiella E, Connor J, Ferry J, Farrell K, Fountain NB, French JA. Reducing placebo exposure in trials: considerations from the Research Roundtable in Epilepsy. Neurology. October 2017; 89(14): 1507–1515.

Galanopoulou AS, French JA, O’Brien T, Simonato M. Harmonization in preclinical epilepsy research: a joint AES/ILAE translational initiative. Epilepsia. November 6, 2017; 58(S4): 7–9.

Galetta KM, Chapman KR, Essis MD, Alosco ML, Gillard D, Steinberg E, Dixon D, Martin B, Chaisson CE, Kowall NW, Tripodis Y, Balcer LJ, Stern RA. Screening utility of the King-Devick Test in mild cognitive impairment and Alzheimer disease dementia. Alzheimer Disease & Associated Disorders. April–June 2017; 31(2): 152–158.

Galetta SL. As the world turns, why do some people adapt to vestibular failure and others do not? Neurology. September 12, 2017; 89(11): 1105–1106.

Galetta SL, Balcer LJ. The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing. Multiple Sclerosis. October 1, 2017; 1352458517721054. epub ahead of print.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. Journal of Neurology. August 2017; 264(8): 1567–1582.

Goni F, Marta-Ariza M, Peyser D, Herline K, Wisniewski T. Production of monoclonal antibodies to pathologic beta-sheet oligomeric conformers in neurodegenerative diseases. Scientific Reports. August 29, 2017; 7(1): 9881.

Gonzalez Caldito N, Antony B, He Y, Lang A, Nguyen J, Rothman A, Ogbuokiri E, Avornu A, Balcer L, Frohman E, Frohman TC, Bhargava P, Prince J, Calabresi PA, Saidha S. Analysis of agreement of retinal-layer thickness measures derived from the segmentation of horizontal and vertical spectralis OCT macular scans. Current Eye Research. December 14, 2017; 1–9. epub ahead of print.

Green S, Blackmon K, Thesen T, DuBois J, Wang X, Halgren E, Devinsky O. Parieto-frontal gyrification and working memory in healthy adults. Brain Imaging and Behavior. March 13, 2017. epub ahead of print.

Gupta VP, Garton ALA, Sisti JA, Christophe BR, Lord AS, Lewis AK, Frey H-P, Claassen J, Connolly ES Jr. Prognosticating functional outcome following intracerebral hemorrhage: the ICHOP Score. World Neurosurgery. May 2017; 101: 577–583.

Gutierrez JV, Kaufmann H, Palma J-A, Mendoza- Santiesteban C, Macefield VG, Norcliffe-Kaufmann L. Founder mutation in IKBKAP gene causes vestibular impairment in familial dysautonomia. Clinical Neurophysiology. November 26, 2017; 129(2): 390–396.

Gutman JM, Levy M, Galetta S, Kister I. Clinical reasoning: a patient with a history of encephalomyelitis and recurrent optic neuritis. Neurology. November 7, 2017; 89(19): e231–e234.

Hainline C, Neophytides A, Borja MJ, Galetta SL. Progressive ataxia and palatal tremor. Neurology: Clinical Practice. August 2017; 7(4): e37–e38.

Hainline C, Rizzo J-R, Hudson TE, Dai W, Birkemeier J, Raynowska J, Nolan RC, Hasanaj L, Selesnick I, Frohman TC, Frohman EM, Galetta SL, Balcer LJ, Rucker JC. Capturing saccades in multiple sclerosis with a digitized test of rapid number naming. Journal of Neurology. May 2017; 264(5): 989–998.

Hainline C, Rucker JC, Zagzag D, Golfinos JG, Lui YW, Liechty B, Warren FA, Balcer LJ, Galetta SL. Tumoral presentation of homonymous hemianopia and prosopagnosia in cerebral amyloid angiopathy-related inflammation. Journal of Neuro-Ophthalmology. March 2017; 37(1): 48–52.

Halvorsen M, Lin Y, Sampson BA, Wang D, Zhou B, Eng LS, Um SY, Devinsky O, Goldstein DB, Tang Y. Whole exome sequencing reveals severe thrombophilia in acute unprovoked idiopathic fatal pulmonary embolism. EBioMedicine. March 2017; 17: 95–100.

Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, French JA, Gil-Nagel A, Hesdorffer DC, Smithson WH, Spitz MC, Walczak TS, Sander JW, Ryvlin P. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents. May–June 2017; 17(3): 180–187.

Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, French JA, Gil-Nagel A, Hesdorffer DC, Smithson WH, Spitz MC, Walczak TS, Sander JW, Ryvlin P. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. April 25, 2017; 88(17): 1674–1680.

Harte-Hargrove LC, French JA, Pitkanen A, Galanopoulou AS, Whittemore V, Scharfman HE. Common data elements for preclinical epilepsy research: standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE. Epilepsia. November 2017; 58(Supplement 4): 78–86.

Hasanaj L, Thawani SP, Webb N, Drattell JD, Serrano L, Nolan RC, Raynowska J, Hudson TE, Rizzo J-R, Dai W, McComb B, Goldberg JD, Rucker JC, Galetta SL, Balcer LJ. Rapid number naming and quantitative eye movements may reflect contact sport exposure in a collegiate ice hockey cohort. Journal of Neuro-Ophthalmology. July 25, 2017. epub ahead of print.

Huang Y, Liu A, Lafon B, Friedman D, Dayan M, Wang X, Bikson M, Devinsky O, Parra LC. Measurements and models of electric fields in the in vivo human brain during transcranial electric stimulation. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. July–August 2017; 10(4): e25–e26.

Huang Y, Liu AA, Lafon B, Friedman D, Dayan M, Wang X, Bikson M, Doyle WK, Devinsky O, Parra LC. Measurements and models of electric fields in the in vivo human brain during transcranial electric stimulation. eLife. February 7, 2017; 6: e18834.

Academic Activities


Inglese M, Petracca M, Mormina E, Achiron A, Straus-Farber R, Miron S, Fabian M, Krieger S, Miller A, Lublin F, Sormani MP. Cerebellar volume as imaging outcome in progressive multiple sclerosis. PloS One. April 24, 2017; 12(4): e0176519.

Jiang X, Shamie I, Doyle WK, Friedman D, Dugan P, Devinsky O, Eskandar E, Cash SS, Thesen T, Halgren E. Replay of large-scale spatio-temporal patterns from waking during subsequent NREM sleep in human cortex. Scientific Reports. December 12, 2017; 7(1): 17380.

Katus L, Frucht S. An unusual presentation of tyrosine hydroxylase deficiency. Journal of Clinical Movement Disorders. December 12, 2017; 4: 18.

Katz JS, Frankel H, Ma T, Zagzag D, Liechty B, Zeev BB, Tzadok M, Devinsky O, Weiner HL, Roth J. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. Child’s Nervous System. April 2017; 33(4): 601–607.

Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? Clinical Autonomic Research. July 2017; 27(Supplement 1): 1–3.

Kaufmann H, Jordan J. The Clinical Autonomic Research journal 2017 and onward. Clinical Autonomic Research. February 2017; 27(1): 1–2.

Kaufmann H, Norcliffe-Kaufmann L, Palma J-A. Reply to “Pure autonomic failure vs. manifest CNS synucleinopathy: relevance of stridor and autonomic biomarkers.” Annals of Neurology. June 2017; 81(6): 910–911.

Kaufmann H, Norcliffe-Kaufmann L, Palma J-A, Biaggioni I, Low PA, Singer W, Goldstein DS, Peltier AC, Shibao CA, Gibbons CH, Freeman R, Robertson D. The natural history of pure autonomic failure: a U.S. prospective cohort. Annals of Neurology. February 2017; 81(2): 287–297.

Kaufmann H, Palma J-A. Neurogenic orthostatic hypotension: the very basics. Clinical Autonomic Research. July 2017; 27(Supplement 1): 39–43.

Khazaei S, Hanis SM, Mansori K, de Dhaem OB, Barr WB, Balcer LJ, Galetta SL, Minen MT. Correspondence regarding: Post-traumatic headache: the use of the sport concussion assessment tool (SCAT-3) as a predictor of post-concussion recovery. Journal of Headache and Pain. August 31, 2017; 18(1): 92.

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. Journal of Clinical Oncology. November 20, 2017; 35(33): 3737–3744.

Kurowski D, Jonczak K, Shah Q, Yaghi S, Marshall RS, Ahmad H, McKinney J, Torres J, Ishida K, Cucchiara B. Safety of endovascular intervention for stroke on therapeutic anticoagulation: multicenter cohort study and meta-analysis. Journal of Stroke & Cerebrovascular Diseases. May 2017; 26(5): 1104–1109.

Harrold GK, Hasanaj L, Moehringer N, Zhang I, Nolan R, Serrano L, Raynowska J, Rucker JC, Flanagan SR, Cardone D, Galetta SL, Balcer LJ. Rapid sideline performance meets outpatient clinic: results from a multidisciplinary concussion center registry. Journal of the Neurological Sciences. August 15, 2017; 379: 312–317.

LaDuke C, Barr W, Brodale DL, Rabin LA. Toward generally accepted forensic assessment practices among clinical neuropsychologists: a survey of professional practice and common test use. The Clinical Neuropsychologist. January 2018; 32(1): 145–164.

Lafon B, Henin S, Huang Y, Friedman D, Melloni L, Thesen T, Doyle W, Buzsaki G, Devinsky O, Parra LC, Liu AA. Low frequency transcranial electrical stimulation does not entrain sleep rhythms measured by human intracranial recordings. Nature Communications. October 31, 2017; 8(1): 1199.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal. August 1, 2017; 1352458517723718. epub ahead of print.

Lavery AM, Waldman AT, Charles CT, Roalstad S, Candee M, Rose J, Belman A, Weinstock-Guttman B, Aaen G, Tillema J-M, Rodriguez M, Ness J, Harris Y, Graves J, Krupp L, Benson L, Gorman M, Moodley M, Rensel M, Goyal M, Mar S, Chitnis T, Schreiner T, Lotze T, Greenberg B, Kahn I, Rubin J, Waubant E. Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders. November 2017; 18: 164–169.

Lehalle D, Mosca-Boidron A-L, Begtrup A, Boute-Benejean O, Charles P, Cho MT, Clarkson A, Devinsky O, Duffourd Y, Duplomb-Jego L, Gerard B, Jacquette A, Kuentz P, Masurel-Paulet A, McDougall C, Moutton S, Olivie H, Park S-M, Rauch A, Revencu N, Riviere J-B, Rubin K, Simonic I, Shears DJ, Smol T, Taylor Tavares AL, Terhal P, Thevenon J, Van Gassen K, Vincent-Delorme C, Willemsen MH, Wilson GN, Zackai E, Zweier C, Callier P, Thauvin-Robinet C, Faivre L. STAG1 mutations cause a novel cohesinopathy characterised by unspecific syndromic intellectual disability. Journal of Medical Genetics. July 2017; 54(7): 479–488.

LeMonda BC, Tam D, Barr WB, Rabin LA. Assessment trends among neuropsychologists conducting sport-related concussion evaluations. Developmental Neuropsychology. April 28, 2017; 42(2): 113–126.

Lewis A, Adams N, Chopra A, Kirschen MP. Organ support after death by neurologic criteria in pediatric patients. Critical Care Medicine. September 2017; 45(9): e916–e924.

Lewis A, Adams N, Chopra A, Kirschen MP. Use of ancillary tests when determining brain death in pediatric patients in the United States. Journal of Child Neurology. October 1, 2017; 32(12): 975–980.

Lewis A, Czeisler BM, Lord AS. Variations in strategies to prevent ventriculostomy-related infections: a practice survey. The Neurohospitalist. January 2017; 7(1): 15–23.

Liberman AL, Zandieh A, Loomis C, Raser-Schramm JM, Wilson CA, Torres J, Ishida K, Pawar S, Davis R, Mullen MT, Messe SR, Kasner SE, Cucchiara BL. Symptomatic carotid occlusion is frequently associated with microembolization. Stroke. February 2017; 48(2): 394–399.

Lin Y, Williams N, Wang D, Coetzee W, Zhou B, Eng LS, Um SY, Bao R, Devinsky O, McDonald TV, Sampson BA, Tang Y. Applying high-resolution variant classification to cardiac arrhythmogenic gene testing in a demographically diverse cohort of sudden unexplained deaths. Circulation: Genomic and Precision Medicine. December 15, 2017; 10(6): e001839. epub ahead of print.

Litao MS, Nossek E, DeSousa K, Favate A, Raz E, Shapiro M, Becske T, Nelson PK. Permanent deployment of the solitaire FRTM device in the basilar artery in an acute stroke scenario. Interventional Neurology. 2018; 7(1–2): 6–11.

Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen Y-DI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dube M-P, Ebeling T, Eiriksdottir G, Esko T, Farmaki A-E, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin M-R, Jensen GB, Jorgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Magi R, Malarstig A, Manichaikul A, Manning AK, Mantyselka P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Muller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O’Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer I, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renstrom F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitziel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif J-C, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghootkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziewska M, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S. Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics. December 2017; 49(12): 1758–1766.

Liu S, Park S, Allington G, Prelli F, Sun Y, Marta-Ariza M, Scholtzova H, Biswas G, Brown B, Verghese PB, Mehta PD, Kwon Y-U, Wisniewski T. Targeting apolipoprotein E/amyloid beta binding by peptoid CPO_abeta17-21 P ameliorates Alzheimer’s disease related pathology and cognitive decline. Scientific Reports. August 14, 2017; 7: 8009. epub ahead of print.

Lloyd-Smith Sequeira A, Rizzo J-R, Rucker JC. Clinical approach to supranuclear brainstem saccadic gaze palsies. Frontiers in Neurology. August 23, 2017; 8; 429.

Louik J, Doumlele K, Hussain F, Crandall L, Buchhalter J, Hesdorffer D, Donner E, Devinsky O, Friedman D. Experiences with premorbid SUDEP discussion among participants in the North American SUDEP Registry (NASR). Epilepsy & Behavior. May 2017; 70(Pt. A): 131–134.

Lupica CR, Hu Y, Devinsky O, Hoffman AF. Cannabinoids as hippocampal network administrators. Neuropharmacology. September 15, 2017; 124: 25–37.

Malaga-Dieguez L, Spencer R, Pehrson LJ, Vento S, Menzer K, Devinsky O, Trachtman H. Early manifestations of renal disease in patients with tuberous sclerosis complex. International Journal of Nephrology and Renovascular Diseases. May 2, 2017; 10: 91–95.


Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, Sisson KA, Koeman J, Weisenberger DJ, Cottingham SL, DeRoos ST, Devinsky O, Winn ME, Cherniack AD, Shen H, Northrup H, Krueger DA, MacKeigan JP. The genomic landscape of tuberous sclerosis complex. Nature Communications. June 15, 2017; 8: 15816.

Meltzer E, Sguigna PV, Subei A, Beh S, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman EM. Retinal architecture and melanopsin-mediated pupillary response characteristics: a putative pathophysiologic signature for the retino-hypothalamic tract in multiple sclerosis. Journal of the American Medical Association—Neurology. May 1, 2017; 74(5): 574–582.

Mendoza-Santiesteban CE, Gabilondo I, Palma JA, Norcliffe-Kaufmann L, Kaufmann H. The retina in multiple system atrophy: systematic review and meta-analysis. Frontiers in Neurology. May 24, 2017; 8: 206.

Mendoza-Santiesteban CE; Palma J-A, Hedges TR III, Laver NV, Farhat N, Norcliffe-Kaufmann L, Kaufmann H. Pathological confirmation of optic neuropathy in familial dysautonomia. Journal of Neuropathology & Experimental Neurology. March 2017; 76(3): 238–244.

Mendoza-Santiesteban CE, Palma J-A, Norcliffe-Kaufmann L, Kaufmann H. Familial dysautonomia: a disease with hidden tears. Journal of Neurology. June 2017; 264(6): 1290–1291.

Mendoza-Santiesteban CE, Palma J-A, Ortuno-Lizaran I, Cuenca N, Kaufmann H. Pathologic confirmation of retinal ganglion cell loss in multiple system atrophy. Neurology. June 6, 2017; 88(23): 2233–2235.

Miller JB, Barr WB. The technology crisis in neuropsychology. Archives of Clinical Neuropsychology. August 2017; 32(5): 541–554.

Milling TJ Jr., Frontera J. Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding. American Journal of Managed Care. April 17, 2017; 23: S67–S80.

Miskin N, Patel H, Franceschi AM, Ades-Aron B, Le A, Damadian BE, Stanton C, Serulle Y, Golomb J, Gonen O, Rusinek H, George AE. Diagnosis of normal-pressure hydrocephalus: use of traditional measures in the era of volumetric MR imaging. Radiology. October 2017; 285(1): 197–205.

Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott C, Weinreb N. Transformation in pre-treatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Registry. American Journal of Hematology. September 2017; 92(9): 929–939.

Modrek AS, Golub D, Khan T, Bready D, Prado J, Bowman C, Deng J, Zhang G, Rocha PP, Raviram R, Lazaris C, Stafford JM, LeRoy G, Kader M, Dhaliwal J, Bayin NS, Frenster JD, Serrano J, Chiriboga L, Baitalmal R, Nanjangud G, Chi AS, Golfinos JG, Wang J, Karajannis MA, Bonneau RA, Reinberg D, Tsirigos A, Zagzag D, Snuderl M, Skok JA, Neubert TA, Placantonakis DG. Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2. Cell Reports. October 31, 2017; 21(5): 1267–1280.

Nascimento FA, Tseng ZH, Palmiere C, Maleszewski JJ, Shiomi T, McCrillis A, Devinsky O. Pulmonary and cardiac pathology in sudden unexpected death in epilepsy (SUDEP). Epilepsy & Behavior. August 2017; 73: 119–125.

Nascimento OJM, Frontera JA, Amitrano DA, Bispo de Filippis AM, da Silva IRF. Zika virus infection-associated acute transient polyneuritis. Neurology. June 2017; 88(24): 2330–2332.

Nelson AB, Moisello C, Lin J, Panday P, Ricci S, Canessa A, Di Rocco A, Quartarone A, Frazzitta G, Isaias IU, Tononi G, Cirelli C, Ghilardi MF. Beta oscillatory changes and retention of motor skills during practice in healthy subjects and in patients with Parkinson’s disease. Frontiers in Human Neuroscience. March 7, 2017; 11: 104.

Nelson LD, Furger RE, Gikas P, Lerner EB, Barr WB, Hammeke TA, Randolph C, Guskiewicz K, McCrea MA. Prospective, head-to-head study of three computerized neurocognitive assessment tools part 2: utility for assessment of mild traumatic brain injury in emergency department patients. Journal of the International Neuropsychological Society. April 2017; 23(4): 293–303.

Nelson LD, Furger RE, Ranson J, Tarima S, Hammeke TA, Randolph C, Barr WB, Guskiewicz KK, Olsen CM, Lerner EB, McCrea M. Acute clinical predictors of symptom recovery in emergency department patients with uncomplicated mild traumatic brain injury (mTBI) or non-TBI injuries. Journal of Neurotrauma. November 17, 2017. epub ahead of print.

Norcliffe-Kaufmann L, Galindo-Mendez B, Garcia-Guarniz A-L, Villarreal-Vitorica E, Novak V. Transcranial Doppler in autonomic testing: standards and clinical applications. Clinical Autonomic Research. August 18, 2017; 1–16. epub ahead of print.

Nwabuobi LA, Pellinen JC, Wisniewski TM. Thymoma-associated panencephalitis: a newly emerging paraneoplastic neurologic syndrome. Neuroimmunology and Neuroinflammation. June 6, 2017; 117–123.

Onorati F, Regalia G, Caborni C, Migliorini M, Bender D, Poh M-Z, Frazier C, Kovitch Thropp E, Mynatt ED, Bidwell J, Mai R, LaFrance WC Jr., Blum AS, Friedman D, Loddenkemper T, Mohammadpour-Touserkani F, Reinsberger C, Tognetti S, Picard RW. Multicenter clinical assessment of improved wearable multimodal convulsive seizure detectors. Epilepsia. November 2017; 58(11): 1870–1879.

Palma J-A, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Movement Disorders Clinical Practice. May–June 2017; 4(3): 298–308.

Palma J-A, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Autonomic Neuroscience: Basic & Clinical. October 23, 2017. In press.

Palma J-A, Norcliffe-Kaufmann L, Perez MA, Spalink CL, Kaufmann H. Sudden unexpected death during sleep in familial dysautonomia: a case-control study. Sleep. August 1, 2017; 40(8): zsx083.

Palma J-A, Spalink C, Barnes EP, Norcliffe-Kaufmann L, Kaufmann H. Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia. Clinical Autonomic Research. December 1, 2017. epub ahead of print.

Patel AS, Sulica L, Frucht SJ. Velopharyngeal dystonia: an unusual focal task-specific dystonia? Tremor and Other Hyperkinetic Movements. July 11, 2017; 7: 356. epub ahead of print.

Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders A, Golfinos JG, Chi AS, Jain R. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower grade gliomas: a TCGA/TCIA project. Clinical Cancer Research. October 15, 2017; 23(20): 6078–6085.

Peters MAK, Thesen T, Ko YD, Maniscalco B, Carlson C, Davidson M, Doyle W, Kuzniecky R, Devinsky O, Halgren E, Lau H. Perceptual confidence neglects decision-incongruent evidence in the brain. Nature: Human Behaviour. July 10, 2017; 0139.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. The Lancet Neurology. October 2017; 16(10): 797–812.

Picard RW, Migliorini M, Caborni C, Onorati F, Regalia G, Friedman D, Devinsky O. Wrist sensor reveals sympathetic hyperactivity and hypoventilation before probable SUDEP. Neurology. August 8, 2017; 89(6): 633–635.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PloS One. August 2, 2017; 12(8): e0180541.

Ramdhani RA, Frucht SJ, Kopell BH. Improvement of post-hypoxic myoclonus with bilateral pallidal deep brain stimulation: a case report and review of the literature. Tremor and Other Hyperkinetic Movements. May 19, 2017; 7:461. epub ahead of print.

Rasouli J, Ramdhani R, Panov FE, Dimov A, Zhang Y, Cho C, Wang Y, Kopell BH. Utilization of quantitative susceptibility mapping for direct targeting of the subthalamic nucleus during deep brain stimulation surgery. Operative Neurosurgery. May 21, 2017. epub ahead of print.

Raynowska J, Rizzo J-R, Rucker JC, Dai W, Birkemeier J, Hershowitz J, Selesnick I, Balcer LJ, Galetta SL, Hudson T. Validity of low-resolution eye-tracking to assess eye movements during a rapid number naming task: performance of the EyeTribe eye tracker. Brain Injury. December 6, 2017; 32(2): 200–208.

Reisberg B, Shao Y, Golomb J, Monteiro I, Torossian C, Boksay I, Shulman M, Heller S, Zhu Z, Atif A, Sidhu J, Vedvyas A, Kenowsky S. Comprehensive, individualized, person-centered management of community-residing persons with moderate-to-severe Alzheimer disease: a randomized controlled trial. Dementia and Geriatric Cognitive Disorders. February 2017; 43(1–2): 100–117.

Reyes A, Thesen T, Kuzniecky R, Devinsky O, McDonald CR, Jackson GD, Vaughan DN, Blackmon K. Amygdala enlargement: temporal lobe epilepsy subtype or nonspecific finding? Epilepsy Research. May 2017; 132: 34–40.

Reynolds AS, Holmes MG, Agarwal S, Claassen J. Phenotypes of early myoclonus do not predict outcome. Annals of Neurology. March 2017; 81(3): 475–476.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche J-D, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent J-L, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Critical Care Medicine. March 2017; 45(3): 486–552.

Academic Activities


Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche J-D, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent J-L, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine. March 2017; 43(3): 304–377.

Rizzo J-R, Fung JK, Hosseini M, Shafieesabet A, Ahdoot E, Pasculli RM, Rucker JC, Raghavan P, Landy MS, Hudson TE. Eye control deficits coupled to hand control deficits: eye-hand incoordination in chronic cerebral injury. Frontiers in Neurology. July 17, 2017; 8: 330. epub ahead of print.

Rizzo J-R, Hosseini M, Wong EA, Mackey WE, Fung JK, Ahdoot E, Rucker JC, Raghavan P, Landy MS, Hudson TE. The intersection between ocular and manual motor control: eye-hand coordination in acquired brain injury. Frontiers in Neurology. June 1, 2017; 8: 227. epub ahead of print.

Rizzo J-R, Hudson TE, Abdou A, Lui YW, Rucker JC, Raghavan P, Landy MS. Disrupted saccade control in chronic cerebral injury: upper motor neuron-like disinhibition in the ocular motor system. Frontiers in Neurology. January 26, 2017; 8: 12. epub ahead of print.

Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. August 2017; 58(8): e96–e100.

Rubenstein R, Chang B, Grinkina N, Drummond E, Davies P, Ruditzky M, Sharma D, Wang K, Wisniewski T. Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. Acta Neuropathologica Communications. April 18, 2017; 5(1): 30.

Rucker JC, Phillips PH. Efferent vision therapy. Journal of Neuro-Ophthalmology. January 4, 2017. epub ahead of print.

Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope. June 2017; 127(6): 1402–1407.

Sala D, Grissom H, Delsole E, Chu M, Godfried D, Karamitopoulos M, Bhattacharyya S, Chu A. Accuracy of activity monitors for measuring walking activity in ambulatory children with cerebral palsy. Developmental Medicine & Child Neurology. September 2017; 59(S3): 83–84.

Salam MT, Montandon G, Genov R, Devinsky O, Del Campo M, Carlen PL. Mortality with brainstem seizures from focal 4-aminopyridine-induced recurrent hippocampal seizures. Epilepsia. September 2017; 58(9): 1637–1644.

Scheffer, IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshe SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang Y-H, Zuberi SM. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. April 2017; 58(4): 512–521.

Scholtzova H, Do E, Dhakal S, Sun Y, Liu S, Mehta PD, Wisniewski T. Innate immunity stimulation via toll-like receptor 9 ameliorates vascular amyloid pathology in Tg-SwDI mice with associated cognitive benefits. The Journal of Neuroscience. January 25, 2017; 37(4): 936–959.

Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. Journal of Headache and Pain. December 2017; 18(1): 34.

Shaw MT, Pawlak NO, Frontario A, Sherman K, Krupp LB, Charvet LE. Adverse childhood experiences are linked to age of onset and reading recognition in multiple sclerosis. Frontiers in Neurology. June 2, 2017; 8: 242. epub ahead of print.

Shibao CA, Kaufmann H. Pharmacotherapy of cardiovascular autonomic dysfunction in Parkinson disease. CNS Drugs. November 2017; 31(11): 975–989.

Singh A, Sabharwal P, Shepherd T. Neuroimaging in epilepsy. In: Koubeissi MZ and Azar NJ (Eds.) Epilepsy Board Review: A Comprehensive Guide. 2017; Springer: 273–292.

Singh A, Trevick S. Epilepsy. In: Moroz A, Flanagan S, and Zaretsky H (Eds.) Medical Aspects of Disability for the Rehabilitation Professionals, 5th Edition. Springer Publishing Company. December 22, 2016; 213–228.

Spalink CL, Barnes E, Palma J-A, Norcliffe-Kaufmann L, Kaufmann H. Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia. Clinical Autonomic Research. August 2017; 27(4): 279–282.

Stahl CM, Frucht SJ. Focal task specific dystonia: a review and update. Journal of Neurology. July 2017; 264(7): 1536–1541.

Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hayes M, Kase CS, Devinsky O, Seshadri S, Friedman D. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure. April 2017; 47: 105–110.

Szaflarski JP, Devinsky O. Cannabinoids and epilepsy—introduction. Epilepsy & Behavior. May 2017; 70(Part B): 277.

Szaflarski JP, Gloss D, Binder JR, Gaillard WD, Golby AJ, Holland SK, Ojemann J, Spencer DC, Swanson SJ, French JA, Theodore WH. Practice guideline summary: use of fMRI in the presurgical evaluation of patients with epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. January 24, 2017; 88(4): 395–402.

Taqui A, Cerejo R, Itrat A, Briggs FBS, Reimer AP, Winners S, Organek N, Buletko AB, Sheikhi L, Cho S-M, Buttrick M, Donohue MM, Khawaja Z, Wisco D, Frontera JA, Russman AN, Hustey FM, Kralovic DM, Rasmussen P, Uchino K, Hussain MS. Reduction in time to treatment in prehospital telemedicine evaluation and thrombolysis. Neurology. April 4, 2017; 88(14): 1305–1312.

Tateishi K, Higuchi F, Miller J, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor T, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP. The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity. Cancer Research. August 1, 2017; 77(15): 4102–4115.

Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer M, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology. November 1, 2017. epub ahead of print.

Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. Journal of Clinical Movement Disorders. April 28, 2017; 4: 10. epub ahead of print.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. December 21, 2017; S1474-4422(17)30470-2. epub ahead of print.

Trevick SA, Lord AS. Post-traumatic stress disorder and complicated grief are common in caregivers of neuro-ICU patients. Neurocritical Care. June 2017; 26(3): 436–443.

Uy P, Lee YSC, Matsuzawa Y, Childs A, Donahue S, Fraser F, Ricker J, Barr W, MacAllister W. Predictability of the sports concussion assessment tool-third edition (SCAT3) on cognitive performance measures. Archives of Physical Medicine and Rehabilitation. December 2017; 98(12): e177. epub ahead of print.

Vaurio L, Karantzoulis S, Barr WB. The impact of epilepsy on quality of life. In: Chiaravalloti N and Goverover Y (Eds.) Changes in the Brain. November 26, 2016. Springer: 167–177.

Wallach AI, Park H, Rucker JC, Kaufmann H. Supranuclear gaze palsy and horizontal ocular oscillations in Creutzfeldt-Jakob disease. Neurology. August 15, 2017; 89(7): 749.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the global multiple system atrophy research roadmap meeting. Neurology. January 9, 2018; 90(2): 74–82.

Wegiel J, Flory M, Kaczmarski W, Brown WT, Chadman K, Wisniewski T, Nowicki K, Kuchna I, Ma SY, Wegiel J. Partial agenesis and hypoplasia of the corpus callosum in idiopathic autism. Journal of Neuropathology & Experimental Neurology. March 1, 2017; 76(3): 225–237.

Wegiel J, Flory M, Kuchna I, Nowicki K, Yong Ma S, Wegiel J, Badmaev E, Silverman WP, de Leon M, Reisberg B, Wisniewski T. Multiregional age-associated reduction of brain neuronal reserve without association with neurofibrillary degeneration or beta-amyloidosis. Journal of Neuropathology & Experimental Neurology. June 1, 2017; 76(6): 439–457.

Weimer JM, Gordon E, Frontera JA. Predictors of functional outcome after subdural hematoma: a prospective study. Neurocritical Care. February 2017; 26(1): 70–79.

Weimer JM, Jones SE, Frontera JA. Acute cytotoxic and vasogenic edema after subarachnoid hemorrhage: a quantitative MRI study. American Journal of Neuroradiology. May 2017; 38(5): 928–934.

William CM, Saqran L, Stern MA, Chiang CL, Herrick SP, Rangwala A, Albers MW, Frosch MP, Hyman BT. Activity-dependent dysfunction in visual and olfactory sensory systems in mouse models of Down syndrome. The Journal of Neuroscience. October 11, 2017; 37(41): 9880–9888.


SELECT PUBLICATIONS: NEUROSURGERY

Altschul D, Biswas A, Nakhla J, Echt M, Gordon D. Novel double catheter technique with detachable microcatheter for the treatment of arteriovenous malformations: a technical note. Surgical Neurology International. December 21, 2016; 7(Supplement 41): S1072–S1074.

Bailes JE, Patel V, Farhat H, Sindelar B, Stone JL. Football fatalities: the first impact syndrome. Journal of Neurosurgery: Pediatrics. January 2017; 19(1): 116–121.

Bayin NS, Frenster J, Sen R, Si S, Modrek AS, Galifianakis N, Dolgalev I, Ortenzi V, Illa-Bochaca I, Khahera A, Serrano J, Chiriboga L, Zagzag D, Golfinos JG, Doyle W, Heguy A, Chesler M, Barcellos-Hoff MH, Snuderl M, Placantonakis DG. Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget. September 12, 2017; 8(39): 64932–64953.

Bayin NS, Ma L, Thomas C, Baitalmal R, Sure A, Fansiwala K, Bustoros M, Golfinos JG, Pacione D, Snuderl M, Zagzag D, Barcellos-Hoff MH, Placantonakis DG. Patient-specific screening using high-grade glioma explants to determine potential radiosensitization by a TGF-β small molecule inhibitor. Neoplasia. December 2016; 18(12): 795–805.

Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, Pacione D, Golfinos J, Kumthekar P, Ghamsari F, Chen L, Lein P, Chetovich DM, Snuderl M, Horbinksi C. Mutant IDH1 and seizures in patients with glioma. Neurology. May 19, 2017; 88(19): 1805–1813.

Chiu AH, DeVries J, O’Kelly C, Riina HA, McDougal I, Tippett J, Wan M, Manoel A, Marotta T. The second generation eClips endovascular clip system: initial experience. Journal of Neurosurgery. March 17, 2017; 1–8. epub ahead of print.

Cohen-Inbar O, Starke RM, Kano H, Huang P, Rodriguez-Mercado R, Almodovar L, Grills I, Mathieu D, Silva D, Abbassy M, Missios S, Lee JYK, Barnett G, Kondziolka D, Lunsford LD, Sheehan JP. Early versus late AVM responders after stereotactic radiosurgery: an international multicenter study. Journal of Neurosurgery. September 2017; 127(3): 503–511.

Cohen-Inbar O, Starke RM, Lee CC, Kano H, Huang P, Kondziolka D, Grills IS, Silva D, Abbassy M, Missios S, Barnett GH, Lunsford LD, Sheehan JP. Stereotactic radiosurgery for brainstem arteriovenous malformations: a multicenter study. Neurosurgery. December 1, 2017; 81(6): 910–920.

Cohen-Inbar O, Xu Z, Lee CC, Wu CC, Chytka T, Silva D, Sharma M, Radwan H, Grills IS, Nguyen B, Siddiqui Z, Mathieu D, Iorio-Morin C, Wolf A, Cifarelli CP, Cifarelli DT, Lunsford LD, Kondziolka D, Sheehan JP. Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. Journal of Neuro-Oncology. October 2017; 135(1): 67–74.

Cordova C, Chi AS, Chachoua A, Kondziolka D, Silverman JS, Shepherd TM, Jain R, Snuderl M. Osimertinib dose escalation induces regression of progressive EGFR T790M-mutant leptomeningeal lung adenocarcinoma. Journal of Thoracic Oncology. November 2017; 12(11): e188–e190.

Day A, Siddiqui A, Meyers P, Jovin T, Derdeyn C, Hoh B, Riina H, Linfante I, Zaidat O, Turk A, Howington J, Mocco J, Ringer A, Veznedargolu E, Khalessi A, Levy E, Woo H, Harbaugh R, Gionnotta S. Training standards in neuroendovascular surgery: program accreditation and practitioner certification. Stroke. July 2017; 48: 2318–2325.

DeSousa K, Nossek E, Potts M, Riina HA. Whom I stent. In: Veznedaroglu, E (Ed.) Controversies in Vascular Neurosurgery. Springer. 2016: 131–137.

Ding D, Starke R, Kano H, Lee JY, Mathieu D, Pierce J, Huang P, Feliciano C, Rodriguez-Mercado R, Almodovar L, Grills IS, Silva D, Abbassy M, Missios S, Kondziolka D, Barnett GH, Lunsford LD, Sheehan JP. Stereotactic radiosurgery for Spetzler-Martin grade III arteriovenous malformations: an international multicenter study. Journal of Neurosurgery. March 2017; 126(3): 859–871.

Ding D, Starke R, Kano H, Lee JYK, Mathieu D, Pierce J, Huang P, Missios S, Feliciano C, Rodriguez-Mercado R, Almodovar L, Grills I, Silva D, Abbassy M, Kondziolka D, Barnett G, Lunsford LD, Sheehan JP. Radiosurgery for unruptured brain arteriovenous malformations: an international multicenter retrospective cohort study. Neurosurgery. June 1, 2017; 80(6): 888–898.

Ding D, Starke R, Kano H, Mathieu D, Huang P, Feliciano C, Rodriguez-Mercado R, Almodovar R, Grills I, Silva D, Abbassy M, Missios S, Kondziolka D, Barnett G, Lunsford LD, Sheehan JP. International multicenter cohort study of pediatric arteriovenous malformations. Part 1: predictors of hemorrhagic presentation. Journal of Neurosurgery: Pediatrics. February 2017; 19(2): 127–135.

Dowd RS, Pourfar M, Mogilner AY. Deep brain stimulation for Tourette syndrome: a single-center series. Journal of Neurosurgery. April 7, 2017; 1–9. epub ahead of print.

Feng R, Oermann EK, Shrivastava R, Gold A, Collins BT, Kondziolka D, Collins SP. Stereotactic radiosurgery for melanoma brain metastases: a comprehensive clinical case series. World Neurosurgery. April 2017; 100: 297–304.

Franceschi AM, Wiggins GC, Mogilner AY, Shepherd T, Chung S, Lui YW. Optimized, minimal specific absorption rate MRI for high-resolution imaging in patients with implanted deep brain stimulation electrodes. American Journal of Neuroradiology. November 2016; 37(11): 1996–2000.

Frenster JD, Inocencio JF, Xu Z, Dhaliwal J, Alghamdi A, Zagzag D, Bayin NS, Placantonakis DG. GPR133 promotes glioblastoma growth in hypoxia. Neurosurgery. September 1, 2017; 64(CN Supplement 1): 177–181.

Golfinos JG. Positioning for cranial surgery. In: Winn HR (Ed.) Youmans and Winn Neurological Surgery, Seventh Edition. November 30, 2016.

Golinko MS, Harter DH, Rickert S, Staffenberg DA. Cerebrospinal fluid fistula for the craniofacial surgeon: a review and management paradigm. Journal of Craniofacial Surgery. February 23, 2017. epub ahead of print.

Grady C, Tanweer O, Zagzag D, Jafar JJ, Huang PP, Kondziolka D. Delayed hemorrhage from the tissue of an occluded arteriovenous malformation after stereotactic radiosurgery: report of 3 cases. Journal of Neurosurgery. June 2017; 126(6): 1899–1904.

Hainline C, Golfinos JG, Liu Y, Liechty B, Zagzag D, Galetta S. Tumoral presentation of homonymous hemianopia and prosopagnosia in cerebral amyloid angiopathy-related inflammation. Journal of Neuro-Ophthalmology. March 2017; 37(1): 48–52.

Hashmonai M, Cameron AEP, Connery CP, Perin N, Licht PB. The etiology of primary hyperhidrosis: a systematic review. Clinical Autonomic Research. December 2017; 27(6): 379–383.

Jubelt LE, Goldfeld KS, Blecker SB, Chung WY, Bendo JA, Bosco JA, Errico TJ, Frempong-Boadu AK, Iorio R, Slover JD, Horwitz LI. Early lessons on bundled payment at an academic medical center. Journal of the American Academy of Orthopaedic Surgeons. September 2017; 25(9): 654–663.

Kano H, Meola A, Yang HC, Guo W, Martinez R, Martinez M, Urgosik D, Liscak R, Sheehan J, Lee JY, Abbassy M, Barnett G, Mathieu D, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for jugular foramen schwannomas: an international multicenter study. Journal of Neurosurgery. November 10, 2017; 1–9. epub ahead of print.

Katlowitz K, Pourfar MH, Israel Z, Mogilner AY. Intraparenchymal cysts following deep brain stimulation: variable presentations and clinical courses. Operative Neurosurgery. October 1, 2017; 13(5): 576–580.

Kolecki R, Dammavalam V, Zahid AB, Hubbard M, Chaudhry O, Reyes M, Han BJ, Wang T, Papas PV, Adem A, North E, Gilbertson DT, Kondziolka D, Huang J, Huang P, Samadani U. Elevated intracranial pressure and reversible eye-tracking changes detected while viewing a film clip. Journal of Neurosurgery. June 2, 2017; 1–8.

Kondziolka D, Rutka JT. Editorial: A concerted effort to publish the best studies in neurosurgery. Journal of Neurosurgery. May 2017; 126(5): 1445–1447.

Lewis A, Lin J, James H, Krok AC, Zeoli N, Healy J, Lewis T, Pacione D. A single-center intervention to discontinue postoperative antibiotics after spinal fusion. British Journal of Neurosurgery. November 2, 2017; 1–5.

Lewis A, Sen R, Hill TC, James H, Lin J, Bhamra H, Martirosyan N, Pacione D. Antibiotic prophylaxis for subdural and subgaleal drains. Journal of Neurosurgery. March 2017; 126(3): 908–912.

Li P, Fu X, Smith NA, Ziobro J, Curiel J, Tenga MJ, Martin B, Freedman S, Cea-Del Rio CA, Oboti L, Tsuchida TN, Oluigbo C, Yaun A, Magge SN, O’Neill B, Kao A, Zelleke TG, Depositario-Cabacar DT, Ghimbovschi S, Knoblach S, Ho CY, Corbin JG, Goodkin HP, Vicini S, Huntsman MM, Gaillard WD, Valdez G, Liu JS. Loss of CLOCK results in dysfunction of brain circuits underlying focal epilepsy. Neuron. October 11, 2017; 96(2): 387–401.e6.

Marotta T, Riina HA, McDougal I, Ricci D, Killer-Oberpfalzer M. Physiologic remodeling of bifurcation aneurysm: pre-clinical results of the eCLIPs device. Journal of Neurosurgery. March 17, 2017; 1–7. epub ahead of print.

McClelland S III, Marascalchi BJ, Passias PG, Protopsaltis TS, Frempong-Boadu AK, Errico TJ. Impact of race and insurance status on surgical approach for cervical spondylotic myelopathy in the United States: a population-based analysis. Spine. February 2017; 42(3): 186–194.

McClelland S III, Marascalchi BJ, Passias PG, Protopsaltis TS, Frempong-Boadu AK, Errico TJ. Operative fusion of multilevel cervical spondylotic myelopathy: impact of patient demographics. Journal of Clinical Neuroscience. May 2017; 39: 133–136.

Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su YH, Krsek M, Nabeel AM, El-Shehaby A, Kareem KA, Martinez-Moreno N, Mathieu D, McShane B, Blas K, Kondziolka D, Grills I, Lee JY, Martinez-Alvarez R, Reda WA, Liscak R, Lee CC, Lunsford LD, Vance ML, Sheehan JP. Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study. Journal of Clinical Endocrinology & Metabolism. November 1, 2017; 102(11): 4284–4291.

Mehta GU, Zenonos G, Patibandla MR, Lin CJ, Wolf A, Grills I, Mathieu D, McShane B, Lee JY, Blas K, Kondziolka D, Lee CC, Lunsford LD, Sheehan JS. Outcomes after stereotactic radiosurgery for foramen magnum meningiomas: an international multicenter study. Journal of Neurosurgery. September 1, 2017; 1–7. epub ahead of print.

Academic Activities


Modrek AS, Golub D, Khan T, Bready D, Prado J, Bowman C, Deng J, Zhang G, Rocha PP, Raviram R, Lazaris C, Stafford JM, LeRoy G, Kader M, Dhaliwal J, Bayin NS, Frenster JD, Serrano J, Chiriboga L, Baitalmal R, Nanjangud G, Chi AS, Golfinos JG, Wang J, Karajannis MA, Bonneau RA, Reinberg D, Tsirigos A, Zagzag D, Snuderl M, Skok JA, Neubert TA, Placantonakis DG. Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2. Cell Reports. October 31, 2017; 21(5): 1267–1280.

Modrek A, Golub D, Khan T, Prado J, Bowman C, Deng J, Zhang G, Rocha P, Raviram R, Lazaris H, Kader M, Dhaliwal J, Chi A, Golfinos J, Tsirigos A, Zagzag D, Snuderl M, Skok J, Neubert T, Placantonakis D. Low-grade astrocytoma core mutations in IDH1, P53 and ATRX cooperate to block differentiation of human neural stem cells via epigenentic repression of SOX2. Neuro-Oncology. May 31, 2017; 19(Supplement 4): iv35.

Mousavi H, Akpinar B, Niranjan A, Agarwal V, Cohen J, Flickinger JC, Kondziolka D, Lunsford LD. The clinical significance of persistent trigeminal nerve contrast enhancement in patients who undergo repeat radiosurgery. Journal of Neurosurgery. July 2017; 127(1): 219–225.

Nossek E, Chalif D, Buciuc R, Gandras E, Anderer EG, Insigna S, Dehdashti A, Setton A. Intraoperative angiography for arteriovenous malformation resection in the prone and lateral positions, using upper extremity arterial access. Operative Neurosurgery. June 1, 2017; 13(3): 352–360.

Nossek E, Zumofen D, Setton A, Potts M, Raz E, Shapiro M, Riina HA, Angeles de Miquel M, Chalif D, Nelson PK. Treatment of distal anterior cerebral artery aneurysms with the Pipeline Embolization Device. Journal of Clinical Neuroscience. January 2017; 35: 133–138.

Pacione D, Sen C. Surgical resection of lower clivus-anterior foramen magnum meningiomas. In: Chapter 29 of Neurosurgical Operative Atlas: Neuro-Oncology, Third Edition. In press.

Pacione D, Tanweer O, Harter DH. The utility of a multimaterial 3D printed model for surgical planning of complex deformity of the skull base and craniovertebral junction. Journal of Neurosurgery. November 2016; 125(5): 1194–1197.

Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clinical Cancer Research. October 15, 2017; 23(20): 6078–6085.

Patibandla MR, Ding D, Kano H, Xu Z, Lee J, Mathieu D, Whitesell J, Pierce J, Huang P, Kondziolka D, Yen CP, Feliciano C, Rodriguez-Mercado R, Almodovar R, Grills I, Silva D, Abbassy M, Missios S, Barnett G, Lunsford LD, Sheehan JP. Stereotactic radiosurgery for Spetzler-Martin grade IV and V arteriovenous malformations: an international multicenter study. Journal of Neurosurgery. September 8, 2017: 1–10.

Pomeraniec IJ, Kano H, Xu Z, Nguyen B, Siddiqui Z, Silva D, Sharma M, Radwan H, Cohen J, Dallapiaza R, Iorio-Morin C, Wolf A, Jane JA, Grills I, Mathieu D, Kondziolka D, Lee CC, Wu CC, Cifarelli C, Chytka T, Barnett G, Lunsford LD, Sheehan JP. Early versus late gamma knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a matched multicenter cohort study. Journal of Neurosurgery. October 27, 2017: 1–10. epub ahead of print.

Potts M, Shapiro M, Zumofen D, Raz E, Nossek E, DeSousa K, Becske T, Riina HA, Nelson PK. Parent vessel occlusion after Pipeline embolization of cerebral aneurysms of the anterior circulation. Journal of Neurosurgery. December 2017; 127(6): 1333–1341.

Pourfar MH, Mogilner AY. Lead angle matters: side effects of deep brain stimulation improved with adjustment of lead angle. Neuromodulation. December 2016; 19(8): 877–881.

Ricci D, Marotta T, Riina HA, Wan M, De Vries J. A training paradigm to enhance performance and safe use of an innovative neuroendovascular device. Journal of Market Access and Health Policy. November 9, 2016; 4.

Roth J, Ber R, Wisoff JH, Hidalgo ET, Limbrick DD, Berger DS, Thomale UW, Schulz M, Cinalli G, Santoro C, Constantini S. Endoscopic third ventriculostomy in patients with neurofibromatosis type 1: a multicenter international experience. World Neurosurgery. November 2017; 107: 623–629.

Schnurman Z, Chin R, Fishkin ER, Huang PP. Maximizing interhospital transfer resources for neurosurgical patients. World Neurosurgery. August 2017; 104: 702–708.

Schnurman Z, Golfinos JG, Roland JT Jr., Kondziolka D. Knowledge silos: assessing knowledge sharing between specialties through the vestibular schwannoma literature. Journal of Neurosurgery. December 1, 2017; 1–8. epub ahead of print.

Sen R, Benjamin C, Riina HA, Pacione D. C2 arteriovenous fistula presenting as a pathologic hangman’s fracture. Journal of Neurosurgery: Spine. March 2017; 26(3): 341–345.

Sen R, Fatterpekar G, Sen C, Golfinos J, Pack J, Gonen O, Kondziolka D, Block T, Prabhu V, Boada F. The role of high-resolution DCE-MRI with golden-angle radial sparse parallel reconstruction in identification of the normal pituitary gland in patients with macroadenomas. American Journal of Neuroradiology. June 2017; 38(6): 1117–1121.

Shepherd TM, Hoch MJ, Cohen BA, Bruno MT, Fieremans E, Rosen G, Pacione D, Mogilner AY. Palliative CT-guided cordotomy for medically intractable pain in patients with cancer. American Journal of Neuroradiology. February 2017; 38(2): 387–390.

Shin SM, Silverman JS, Bowden G, Mathieu D, Yang HC, Lee CC, Szelemej P, Kaufmann A, Cohen-Inbar O, Sheehan JP, Niranjan A, Lunsford LD, Kondziolka D. Relapsed or refractory primary central nervous system lymphoma radiosurgery: report of the International Gamma Knife Research Foundation. Journal of Radiosurgery & SBRT. February 21, 2017; 4(4): 247–253.

Sindelar B, Bailes J, Sherman S, Finan J, Stone JL, Lee J, Zhou Y, Patel V, Smith D. Effects of internal jugular vein compression on intracranial hemorrhage in a porcine controlled cortical impact model. Journal of Neurotrauma. April 15, 2017; 34(8): 1703–1709.

Snuderl M, Zhang G, Wu P, Jennings TS, Shroff S, Ortenzi V, Jain R, Cohen B, Reidy JJ, Dushay MS, Wisoff JH, Harter DH, Karajannis MA, Fenyo D, Neubert TA, Zagzag D. Endothelium-independent primitive myxoid vascularization creates invertebrate-like channels to maintain blood supply in optic gliomas. American Journal of Pathology. August 2017; 187(8): 1867–1878.

Sone JY, Kondziolka D, Huang J, Samadani U. Helmet efficacy against concussion and traumatic brain injury: a systematic literature review. Journal of Neurosurgery. March 2017; 126(3): 768–781.

Starke RM, Ding D, Kano H, Mathieu D, Huang P, Feliciano C, Rodriguez-Mercado R, Almodovar R, Grills I, Silva D, Abbassy M, Missios S, Kondziolka D, Barnett G, Lunsford LD, Sheehan JP. International multicenter cohort study of pediatric arteriovenous malformations. Part 2: outcomes after stereotactic radiosurgery. Journal of Neurosurgery: Pediatrics. February 2017; 19(2): 136–148.

Starke R, Kano H, Ding D, Lee JYK, Mathieu D, Whitesell J, Pierce J, Huang P, Kondziolka D, Feliciano C, Rodriguez-Mercado R, Almodovar L, Pieper D, Grills I, Silva D, Abbassy M, Missios S, Barnett G, Lunsford LD, Sheehan JP. Stereotactic radiosurgery for arteriovenous malformations: evaluation of long-term outcomes in a multicenter cohort. Journal of Neurosurgery. January 2017; 126(1): 36–44.

Stone JL, Selner AN, Patel VA. Historical perspective on the development of cerebral localization, cerebral cortical motor stimulation, and sensory evoked potentials. In: Byrne, RW (Ed.) Functional Mapping of the Cerebral Cortex: Safe Surgery in Eloquent Brain. Springer. 2016; 1–21.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathology. December 2016; 132(6): 917–930.

Wolf A, Donahue B, Silverman JS, Chachoua A, Lee JK, Kondziolka D. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. Journal of Neuro-Oncology. August 2017; 134(1): 139–143.

Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B, Golfinos J, Silverman J, Kondziolka D. Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. Journal of Neurosurgery. January 2018; 128(1): 23–31.

Wolf A, Tyburczy A, Ye JC, Fatterpekar G, Silverman J, Kondziolka D. The relationship of dose to nerve volume in predicting pain recurrence after stereotactic radiosurgery in trigeminal neuralgia. Journal of Neurosurgery. May 19, 2017; 1–6. epub ahead of print.

Zumofen D, Rychen J, Roethlisberger M, Taub E, Kalbermatten D, Nossek E, Potts M, Guzman R, Riina HA, Mariani L. A systematic review of the literature on the transciliary supraorbital keyhole approach. World Neurosurgery. February 2017; 98: 614–624.


Faculty

NEUROSURGERY

Erich G. Anderer Mitchell Chesler Werner K. Doyle Anthony K. Frempong-Boadu John G. Golfinos James B. Golomb David S. Gordon David H. Harter E. Teresa Hidalgo Paul P. Huang Jafar J. Jafar Douglas S. Kondziolka John I. Miller Alon Y. Mogilner Donato R. Pacione Noel I. Perin Dimitris G. Placantonakis Michael H. Pourfar Margaret E. Rice Howard A. Riina Stephen M. Russell Chandranath Sen Michael L. Smith James Stone Lee Tessler Jeffrey H. Wisoff Amanda L. Yaun

NEUROLOGY

AUTONOMIC DISORDERSHoracio Kaufmann Lucy J. Norcliffe-Kaufmann Carlos E. Mendoza-Santiesteban Jose-Alberto Palma

CHILD NEUROLOGYJeffrey C. Allen Judith Bluvstein Mary-Lynn Y. Chu Irving FishSandra L. Forem Lauren B. Krupp Josiane LaJoie Heather A. Lau Daniel K. Miles Aaron Nelson Robin E. Smith Hae-Ri Song John T. Wells Kaleb H. Yohay

CLINICAL NEUROPHYSIOLOGYAleksandar Beric Cristina M. Drafta Kiril Kiprovski Athena M. Lolis Anna Shor Suying L. Song Ming Xu

COGNITIVE NEUROLOGYSonja Blum Allal Boutajangout Tracy Butler Eleanor S. Drummond Silvia Fossati Elkhonon Goldberg Fernando R. Goni Lindsey J. Gurin Karyn D. Marsh Arjun V. Masurkar Joanna E. Pankiewicz Julia A. Rao Martin Sadowski Henrieta Scholtzova Melanie B. Shulman Thomas M. Wisniewski

EPILEPSYKaren E. Blackmon Judith Bluvstein Michael Boffa Lucia A. Melloni Buljevic Jocelyn Y. Cheng Orrin Devinsky Patricia C. Dugan Adeen Flinker Jacqueline A. French Daniel Friedman Deana M. Gazzola Jennifer Gelinas Eric Halgren Biyu J. He Scott E. Hirsch Manisha G. Holmes Amy C. Jongeling Marshall J. Keilson Josiane LaJoie Karen L. Lee Beth A. Leeman-Markowski Anli A. Liu Daniel J. Luciano Michael R. Meager Lucia A. Melloni-Buljevic Daniel K. Miles Chris Morrison Siddhartha S. Nadkarni Heath R. Pardoe Christina Pressl Alcibiades J. Rodriguez Rebecca J. Scott Andre V. Strizhak Thomas Thesen Blanca Vazquez

GENERAL NEUROLOGYRobert S. April Lennart Belok Myrna I. Cardiel Dominique Cozien Arthur Farkash Farng-Yang A. Foo Sun-Hoo Foo James B. Golomb Brian W. Hainline Elvira Kamenetsky Marshall J. Keilson Arielle M. Kurzweil David N. LevineMitra Nirmala

Andreas N. Neophytides Dora S. Pinkhasova Perrin A. Pleninger Neil S. Rosenthal Alexander Schick David Schick Andre V. Strizhak Daniel M. Torres Harold J. Weinberg Ericka Wong David S. Younger Xishan Zhang

GLOBAL HEALTHJaydeep M. Bhatt Jerome H. Chin

HEADACHE MEDICINESait Ashina Thomas Berk Adelene E. Jann Suja Johnkutty Valeriya Levitan Mia T. Minen Lawrence C. Newman

MULTIPLE SCLEROSISJoshua H. Bacon Anita L. Belman Robert W. Charlson Leigh E. Charvet Jacqueline Friedman Albert Goodgold Josef M. Gutman Jonathan E. Howard Marshall J. Keilson Ilya Kister Lauren B. Krupp Krupa S. Pandey Lana Zhovtis RyersonJames L. Salzer Rachel Ventura Robyn Wolintz

NEUROCRITICAL CAREBarry M. Czeisler Jennifer A. Frontera Ariane K. Lewis Aaron S. Lord

NEURO-EPIDEMIOLOGYLaura J. Balcer Bernadette Boden-Albala Leigh E. Charvet Jacqueline A. French Daniel Friedman Aaron S. Lord Arjun V. Masurkar Mia T. Minen Heidi Schambra Sujata P. Thawani

NEUROGENETICSHeather A. Lau

NEUROMUSCULAR MEDICINEJaydeep M. Bhatt Myrna I. Cardiel Mary-Lynn Y. Chu Farng-Yang A. Foo Kiril Kiprovski Arielle M. Kurzweil Patrick Kwon Athena M. Lolis Perrin A. Pleninger Howard W. Sander David Schick Sujata P. Thawani Daniel M. Torres Janice F. Wiesman Ericka Wong

NEURO-ONCOLOGYJeffrey C. Allen Andrew S. Chi Sylvia C. Eisele Claude Macaluso Allan E. Rubenstein Kaleb H. Yohay

NEURO-OPHTHALMOLOGYLaura J. Balcer Mohammad Fouladvand Steven L. Galetta Cinthi Pillai Janet C. Rucker Floyd A. Warren

NEURO-OTOLOGYCatherine Cho

NEUROPSYCHOLOGYWilliam B. Barr Leigh E. Charvet Kathleen A. Jantzen Gianna Locascio Chris Morrison

PARKINSON’S AND MOVEMENT DISORDERSGiovanni F. Abbruzzese Milton C. Biagioni Miroslaw S. Brys Alessandro Di Rocco Arash Fazl Andrew S. Feigin Jori E. Fleisher Steven J. Frucht Maria Felice M. Ghilardi Rebecca M. Gilbert Ioannis Isaias Amy C. Lemen Michael H. Pourfar Angelo Quartarone Ritesh A. Ramdhani David M. Swope

VASCULAR NEUROLOGYBernadette Boden-Albala Albert S. Favate Koto Ishida

Howard A. Riina Sara K. Rostanski Heidi Schambra Jose L. Torres Cen Zhang Ting Zhou

NYC HEALTH + HOSPITALS/BELLEVUE Laura S. Boylan Ludmilla Bronfin Regina R. DeCarlo Audrey Halpern Saran Jonas Nancy L. Mueller Aaron Nelson Melissa J. Nirenberg Robert I. Pfeffer Perrin A. Pleninger Anuradha Singh Janice F. Wiesman Ericka Wong

VETERANS AFFAIRS NEW YORK HARBOR HEALTH CARE SYSTEMZuzana Belisova-Gyure Alla FeldbargJacqueline Friedman Richard M. Hanson Emile M. Hiesiger Martin Sadowski Robert Staudinger Thomas M. Wisniewski

NYU LANGONE HOSPITAL—BROOKLYNNada G. Abou-Fayssal Karthikeyan M. Arcot Sait Ashina Michael Boffa Clara D. Boyd Alexander B. Chervinsky Julie DeBacker Jeffrey Farkas Jennifer A. Frontera David S. Gordon Katarzyna Jakubowska- SadowskaAmy C. Jongeling David E. Kahn Sun Kim Patrick Kwon Jeremy Liff Gianna Locascio Anthony G. Maniscalco Michelle Molina Leonard A. Pace Nikolaos Papamitsakis Matthew D. Sanger George P. Tavoulareas Ambooj Tiwari David Turkel-Parrella Blanca Vazquez Ting Zhou


Leadership

NEUROSURGERY

John G. Golfinos, MDAssociate Professor of Neurosurgeryand OtolaryngologyChair of the Department of NeurosurgeryCo-Director, Brain Tumor CenterInvestigator, Neuroscience Institute

Erich G. Anderer, MDAssistant Professor of NeurosurgeryChief of Neurosurgery, NYU Langone Hospital—Brooklyn

Mitchell Chesler, MD, PhDProfessor of Neurosurgeryand Neuroscience and PhysiologyVice Chair of ResearchAssociate Director, Medical ScienceTraining Program

Anthony K. Frempong-Boadu, MDAssociate Professor of Neurosurgeryand Orthopedic SurgeryDirector, Division of Spinal NeurosurgeryCo-Director, Spine Center

David H. Harter, MDAssociate Professor of NeurosurgeryDirector, Neurosurgery Residency Training ProgramDirector, Pediatric Cerebral Endoscopy

Paul Huang, MDAssistant Professor of NeurosurgeryDirector, Neurosurgery Service,NYC Health + Hospitals/Bellevue

Jafar J. Jafar, MDProfessor of NeurosurgeryDirector, Division of Cerebrovascular Surgery

Douglas S. Kondziolka, MD, MScGray Family Professor of NeurosurgeryVice Chair of Clinical ResearchDirector, Center for Advanced Radiosurgery

Alon Mogilner, MD, PhDAssociate Professor of Neurosurgery and AnesthesiologyDirector, Center for Neuromodulation

Noel I. Perin, MDAssociate Professor of NeurosurgeryDirector, Minimally Invasive Spinal Surgery

Howard A. Riina, MDProfessor of Neurosurgery, Neurology, and RadiologyVice Chair of the Department of NeurosurgeryDirector, Endovascular SurgeryAssociate Director, Neurosurgery ResidencyTraining ProgramDirector, Advanced Stroke Center

Chandranath Sen, MDProfessor of NeurosurgeryVice Chair for EducationDirector, Skull Base Surgery

James L. Stone, MDProfessor of NeurosurgeryChief of Service, VA NY Harbor Health Care System

Lee E. Tessler, MDAssociate Professor of NeurosurgeryChief of Neurosurgery, NYU Winthrop Hospital

Jeffrey H. Wisoff, MDProfessor of Neurosurgery and PediatricsDirector, Division of Pediatric Neurosurgery

NEUROLOGY

Steven L. Galetta, MDPhilip K. Moskowitz, MD Professor and Chair of NeurologyProfessor of Neurology and OphthalmologyChair of the Department of Neurology

Laura J. Balcer, MDProfessor of Neurology, Ophthalmology, and Population HealthVice Chair of the Department of Neurology

William B. Barr, PhDAssociate Professor of Neurology and PsychiatryDirector, Neuropsychology Program

Aleksandar Beric, MDProfessor of Neurology, Neurosurgery, Orthopedic Surgery, and Rehabilitation MedicineDirector, Division of Clinical Neurophysiology

Jaydeep M. Bhatt, MDClinical Associate Professor of NeurologyDirector, Division of Global Health

Andrew S. Chi, MD, PhDAssistant Professor of Medicine, Neurology, and NeurosurgeryDirector, Neuro-Oncology ProgramCo-Director, Brain Tumor Center

Catherine Cho, MDClinical Associate Professor of Neurology and Otolaryngology Director, Division of Neuro-Otology

Orrin Devinsky, MDProfessor of Neurology, Neurosurgery, and PsychiatryDirector, Division of Epilepsy

Albert S. Favate, MDAssociate Professor of NeurologyDirector, Division of Vascular Neurology

Andrew S. Feigin, MDProfessor of NeurologyAssociate Chair of Neurology, Clinical Research Executive Director, Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders

Jennifer A. Frontera, MDProfessor of Neurology Chief of Neurology, NYU Langone Hospital—Brooklyn Vice Chair of Neurology, NYU Langone Hospital—Brooklyn

Steven J. Frucht, MD Professor of NeurologyAssociate Chair of Neurology, Clinical Practices Director, Division of Parkinson’s and Movement Disorders

Richard M. Hanson, MD Clinical Associate Professor of NeurologyChief of Service, VA NY Harbor Health Care System

Horacio Kaufmann, MDFelicia B. Axelrod Professor of Dysautonomia ResearchProfessor of Medicine and PediatricsDirector, Division of Autonomic Disorders

Lauren B. Krupp, MDNancy Glickenhaus Pier Professor of Pediatric NeuropsychiatryDirector, Division of Multiple Sclerosis

Aaron S. Lord, MDAssistant Professor of Neurology and NeurosurgeryDirector, Division of Neurocritical Care

Lawrence C. Newman, MDProfessor of NeurologyDirector, Division of Headache Medicine

Janet C. Rucker, MDBernard A. and Charlotte Marden Professor of NeurologyProfessor of OphthalmologyChief, Division of Neuro-OphthalmologyDirector, Neuro-Ophthalmology Fellowship Program

Howard W. Sander, MDProfessor of Neurology, Psychiatry, and Anesthesiology, Perioperative Care, and Pain MedicineAssociate Chair, EducationDirector, Division of Neuromuscular Medicine

Heidi Schambra, MDAssistant Professor of Neurology and Rehabilitation MedicineDirector, Division of Neuro-Epidemiology

Anuradha Singh, MDClinical Professor of NeurologyDirector, Neurology Service, NYC Health + Hospitals/Bellevue

Harold J. Weinberg, MD, PhDClinical Professor of NeurologyAssociate Chair, Clinical AffairsDirector, Division of General NeurologyChief, Neurology Service

John T. Wells, MDClinical Professor of NeurologyDirector, Division of Child Neurology

Thomas M. Wisniewski, MDGerald J. and Dorothy R. Friedman Professor of Neurology Professor of Pathology and Psychiatry Associate Chair, ResearchDirector, Division of Cognitive Neurology

For more information about our physicians, services, and locations, visit nyulangone.org


Leadership

* Numbers represent FY17 (Sept 2016–Aug 2017) and include NYU Langone Hospital—Brooklyn

Kenneth G. Langone

Chair, Board of Trustees

Robert I. Grossman, MD

Saul J. Farber Dean and Chief Executive Officer

Steven B. Abramson, MD

Senior Vice President and Vice Dean for Education, Faculty, and Academic Affairs

Dafna Bar-Sagi, PhD

Senior Vice President and Vice Dean for Science, Chief Scientific Officer

Andrew W. Brotman, MD

Senior Vice President and Vice Dean for Clinical Affairs and Strategy, Chief Clinical Officer

Michael T. Burke

Senior Vice President and Vice Dean, Corporate Chief Financial Officer

Richard Donoghue

Senior Vice President for Strategy, Planning, and Business Development

Annette Johnson, JD, PhD

Senior Vice President and Vice Dean, General Counsel

Grace Y. Ko

Senior Vice President for Development and Alumni Affairs

Kathy Lewis

Senior Vice President for Communications and Marketing

Joseph Lhota

Senior Vice President and Vice Dean, Chief of Staff

Vicki Match Suna, AIA

Senior Vice President and Vice Dean for Real Estate Development and Facilities

Nader Mherabi

Senior Vice President and Vice Dean, Chief Information Officer

Robert A. Press, MD, PhD

Senior Vice President and Vice Dean, Chief of Hospital Operations

Nancy Sanchez

Senior Vice President and Vice Dean for Human Resources and Organizational Development and Learning

NYU LANGONE HEALTH

5,087Original Research Papers

549,707Square Feet of Research Space

$359MNIH Funding

$364MTotal Grant Revenue

1,519Beds

98Operating Rooms

172,072Emergency Room Visits

68,884Patient Discharges

4,500,000Outpatient Faculty Practice Visits

9,654Births

3,633Physicians

5,104Nurses

516MD Candidates

85MD/PhD Candidates

263PhD Candidates

418Postdoctoral Fellows

1,327Residents and Fellows

NYU LANGONE BY THE NUMBERS*

NEW YORK UNIVERSITY

William R. Berkley

Chair, Board of Trustees

Andrew Hamilton, PhD

President


1 MESSAGE FROM THE CHAIRS

2 FACTS & FIGURES

4 2017 IN BRIEF

10 2017 IN DEPTH

11 Epilepsy Advances Target Seizure Activity, Severity

13 Complex Case: Resection of a Deep Thalamic Cavernous Malformation

16 Gamma Knife Radiosurgery—Versatility in Tumor and AVM Treatment

18 Novel Optical Assessments Offer Insight into Neurological Conditions

20 Complex Case: Intramedullary Cavernoma Calls for Intervention

22 Promising Research Fuels the Pursuit of New Alzheimer’s Pathways

24 Novel Neuromodulation Approaches for Movement Disorders

26 ACADEMIC ACTIVITIES

34 FACULTY

35 LEADERSHIP

Contents

On the cover: Nerve fibers

Produced by: Office of Communications and Marketing, NYU Langone Health Writer: Royce Flippin Design: Ideas On Purpose, www.ideasonpurpose.com Primary Photographer: Karsten Moran Printing: Allied Printing Services, Inc.

NYU LANGONE HEALTH

550 First Avenue, New York, NY 10016

NYULANGONE.ORG

Neurology & Neurosurgery2017 YEAR IN REVIEW

AdvancedTECHNOLOGY FOR NEUROSURGICAL IMAGING

214NEUROLOGY FACULTY

# 10IN U.S. NEWS & WORLD REPORT

neurology & neurosurgery - nyulangone.org · philip k. moskowitz, md professor and chair of...

Documents